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Abstract 
 
 As the deadliest of all gynecologic malignancies, ovarian cancer has a 
death rate of more than 50% due to late detection and diagnosis of the disease 
and intrinsic or acquired resistance to current therapeutic regimens. The 
identification of robust biomarkers for early detection will have a substantial 
impact on survival rates, while prognostic molecular markers may allow for 
efficacious targeted therapeutic strategies.  
 Progesterone plays a pivotal role in the development and progression of 
hormone-regulated tumors. In the breast, progesterone promotes a proliferative, 
pro-survival response, but inhibits growth in the uterus and ovary. The opposing 
biology in ovarian versus breast cancer cells may be largely dependent on cell 
context. The paradoxical effects of progesterone observed in ovarian relative to 
breast cancer cells may be attributed to actions of the nuclear progesterone 
receptor (PR) and its isoforms, PR-B and PR-A and their relative regulation (i.e. 
by post-translational modifications and co-factor binding partners), differential 
cross-talk between PR and growth factor-mediated signaling pathways (i.e. 
protein kinases), and/or altered expression levels in the target cells. In contrast to 
breast cancer, the detailed mechanisms of progesterone action in ovarian cancer 
are poorly understood. The goals of our studies were to determine the level of 
PR isoform expression in primary and cell models of ovarian cancer, to define the 
biological consequences of PR expression and activity on ovarian cancer cell 
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biology, and to identify the key cofactor(s) required for mediating PR-dependent 
signaling actions.   
 We demonstrated that ligand-activated PR-B induced a non-proliferative 
cell fate, known as cellular senescence, through a FOXO1-dependent 
mechanism in ovarian cancer cells. PR-B and FOXO1 were co-recruited to the 
same PRE-containing region of the upstream promoter of p21 upon progestin 
(R5020) treatment. Both proteins are required to cooperatively activate p21 
expression based on data from PR-null control cells and lentiviral-delivered 
shRNA FOXO1-knockdown studies. Stable knock-down of FOXO1 inhibited 
progestin-induced p21 expression in ES-2 cells stably expressing GFP-tagged 
PR-B and blocked PR-dependent cellular senescence. 
 Next, we investigated the biological consequences of PR isoform-specific 
gene regulation in ovarian cancer models, as well as directly compared PR 
isoform-selective transcriptomes between ovarian and breast cancer models. In 
ovarian cancer cells, PR-A is relatively insensitive to hormone, and PR-B (but not 
PR-A) is capable of inducing FOXO1 and p21 expression required for progestin-
mediated cellular senescence in ovarian cancer cells. Furthermore, our studies 
revealed FOXO1 as a critical cofactor and determinant for the regulation of PR 
hormone sensitivity. Namely, activated FOXO1 confers PR-B-like behavior to 
PR-A, and in the presence of FOXO1, PR-A trans-activates classical PR-B target 
genes and induces robust cellular senescence. Finally, we utilized a novel ex 
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vivo explant culture system of human primary ovarian tumors that recapitulated 
our in vitro findings.  
 Significantly, identifying the mechanisms governing PR-A versus PR-B 
specific gene regulation driven by FOXO1 may provide a means to promote PR-
B driven cellular senescence in ovarian cancer and provide clues to inducing the 
protective actions of PR-A in other hormone-driven cancers, such as breast and 
uterine. PR-targeted strategies could provide a safe and useful means to improve 
treatment outcomes and increase overall ovarian cancer patient survival.
  vi 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Progesterone: sources and functions 
 Progesterone is a steroid hormone that is produced primarily by the 
corpus luteum in the ovaries during the second half of the menstrual cycle (i.e. 
luteal phase). Progesterone is also produced, to a lesser extent, in the adrenal 
glands and, during pregnancy, the placenta. Thus, cyclical hormone exposure 
beginning at menarche and ending in menopause occurs monthly and regulates 
the growth and differentiation of specialized tissues within the reproductive tract 
and breast tissues.1, 2 Pregnancy interrupts this process, and is characterized by 
high progesterone levels, which are required for fetal development, breast 
development for lactation, maintenance of uterine/placental integrity, and 
myometrial quiescence.3  
1.2 Epidemiological role of progesterone in ovarian tumors 
 A considerable body of epidemiological data suggests that progesterone 
and progestins play a protective role against ovarian carcinogenesis. 
Progesterone deficiencies due to increasing age, infertility, or a genetic LOH at 
the PR gene locus are associated with increased ovarian cancer risk.4, 5 In 
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contrast, elevated progesterone levels decrease ovarian cancer risk. The 
protective effect of pregnancy has been documented in Asian, European, and 
North American populations6; progesterone levels during pregnancy are 10-fold 
greater than luteal phase levels measured during the menstrual cycle. Similarly, 
hormonal oral contraceptive use has been consistently associated with a reduced 
risk. In an analysis of 20 epidemiological studies between 1970-1991, it was 
estimated that a 35% reduction in risk was associated with ever-use of oral 
contraceptives.7 Additionally, the risk of ovarian cancer is correlated with duration 
of oral contraceptive use: 10-12% decrease in risk with one year of use and 50% 
decrease after 5 years of use in both nulliparous and parous women.7 
Progesterone exerts a protective effect on ovarian cancer risk by reducing 
ovulation through elevated progesterone levels from oral contraceptive use or 
during pregnancy. Furthermore, PR expression, the PR-B isoform specifically8-10, 
in ovarian tumors is a favorable prognostic marker associated with longer 
progression-free survival.8, 11-18 
 BRCA1/2 mutations may alter the production and sensitivity to estrogen 
and progesterone as carriers have an increased risk for breast and ovarian 
cancer. Studies in mice carrying a BRCA1 mutation in ovarian granulosa (i.e. 
hormone producing) cells19-21 and in humans with either a BRCA1 or BRCA2 
mutation22 demonstrated that BRCA mutations confers higher serum (circulating) 
levels of both estrogen and progesterone. Moreover, serous tubal intra-epithelial 
carcinoma in the distal end of the fallopian tube was discovered in 10-15% of 
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BRCA carriers who had prophylactic salpingo-oophorectomy.23, 24 Ultimately, little 
mechanistic information exists related to the impact that hormones have on the 
prevention and/or pathogenesis of ovarian cancer. The evidence related to the 
pathophysiology of ovarian cancer suggests a strong connection with estrogen, 
progesterone, and, more recently, androgen actions in the development and 
progression of ovarian cancer. Steroid hormone action in ovarian cancer is 
grossly understudied, and there is an urgent need to focus on the early events 
related to the contribution of hormones in the context of altered signaling events 
(loss of p53 or PTEN, elevation of AKT signaling) that predisposes women 
including those with BRCA mutations to an increased risk of breast and ovarian 
cancer. 
1.3 Progesterone Receptor Isoforms 
 The actions of progesterone are mediated through the nuclear 
progesterone receptors (PRs). PR belong to the steroid receptor superfamily of 
related ligand-activated transcription factors that includes estrogen, androgen, 
mineralocorticoid, and glucocorticoid receptors.25 PRs are composed of a 
modular domain structure that includes an N-terminal domain (NTD), DNA 
binding domain (DBD), hinge region (H), and hormone binding domain (HBD) 
(Figure 1). There are three PR isoforms: full length PR-B, N-terminally truncated 
PR-A (-164 amino acids), and the non-functional PR-C, consisting of only the 
hinge region and HBD. PR-B and PR-A are typically expressed in equimolar 
ratios and function as ligand activated transcription factors, whereas PR-C 
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expression is limited and may serve largely to sequester ligand, as it is incapable 
of binding DNA.26  
 
Figure 1-1: The post-translational modifications of progesterone receptors.   
17 post-translational modification sites that impact PR-mediated transcriptional action. 
PR-B, but not PR-A, includes 164 additional amino acids in the NTD (called B upstream 
segment) where the third activation function domain and multiple phosphorylation sites 
are located. PR-B and PR-A are transcribed from the same gene and their protein 
isoforms are identical from amino acids 165-993. The protein tertiary structure results in 
a folding at the hinge region between the DBD and HBD. Post-translational modifications 
(phosphorylation, acetylation, and SUMOylation) can occur basally or in response to 
ligand binding and affect PR transcriptional activity. In particular, activated protein kinase 
pathways input to PR via phosphorylation and these pathways are heavily altered in 
breast, ovarian, and uterine carcinomas. Numbering reflects amino acid residue 
positions. The color of phosphorylation sites is associated with the following: red = 
MAPK; green = CDK2; yellow = CK2; purple = unknown kinases. PR, progesterone 
receptor protein isoforms A, B, or C; NTD, N-(amino)-terminal domain; DBD, DNA 
binding domain; H, hinge region; HBD, hormone binding domain; AF, activation function 
1-3; P, phosphorylation; A, acetylation; SUMO, small ubiquitin-like modifier 
(SUMOylation). 
 
 
 Progesterone diffuses through the lipid membrane and interacts with the 
HBD of PR-A or PR-B. This interaction alters the conformation of PR favoring 
nuclear localization, dimerization (A:A, B:B, or A:B dimers are possible), and 
DNA binding. Classically, PR binds Progesterone Response Elements (PRE) in 
the DNA and recruits cofactors and transcriptional machinery to initiate gene 
transcription. PR can also participate in the transcriptional complexes of other 
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DNA bound transcription factors to alter gene expression.27-30 Non-classical or 
extranuclear signaling of PR involves PR direct binding to kinases complexed at 
the membrane with growth factor receptors (such as EGFR or IGF1R) to initiate 
rapid activation of downstream signaling cascades.31, 32 For example, 
progesterone induces rapid activation of ERK1/2 MAP kinase pathways, which 
function to activate a variety of transcription factors via phosphorylation events, 
including PR itself.28, 31, 32 Notably, PR-B, but not PR-A, is capable of rapid 
signaling, likely in part owing to its relatively increased occupancy in the 
cytoplasm.33  
 Although PR isoforms share structural and sequence similarity, PR-A and 
PR-B are functionally distinct transcriptional regulators exhibiting recruitment to 
different subsets of PR-target gene promoters34, 35. PR-B, but not PR-A, functions 
outside of the nucleus to rapidly activate protein kinases (MAPK, AKT, c-Src) in 
part by a ligand-induced interaction between PR and c-Src kinase.31, 32, 36 Rapid 
progesterone-induced c-Src/MAPK activation phosphorylates PR-B37, 38 (Figure 
1), and potentiates the actions of nuclear PR to specific target promoter regions. 
Recently, MAPKs (namely ERK2 and p38 MAPK) have been shown to participate 
in transcriptional complexes as part of steroid hormone receptor binding 
partners.39, 40 Thus, differences between PR isoform activities may be attributed 
to differential cross-talk between PRs and protein kinases downstream of growth 
factor-mediated signaling pathways and/or differential recruitment of required co-
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factors. It is unknown how PR isoform activities are regulated in ovarian cancer 
cells.  
1.4 PR as a prognostic marker in ovarian tumors 
 Recent studies have revealed that ‘ovarian cancer’ is not a single disease, 
and a significant portion of ovarian tumors may not originate from ovarian tissue. 
At present, five major histopathological subtypes of epithelial ovarian cancer 
have been characterized and are phenotypically and molecularly distinct41: high-
grade serous, low-grade serous, endometrioid, clear cell, and mucinous. 
Pathological and genomic studies indicate that cancers of these major subtypes 
are frequently derived from non-ovarian tissues that have metastasized and 
homed to the ovary (Figure 2). Clear cell and endometrioid ovarian cancers are 
derived either from the cervix or endometriosis, which itself is associated with 
retrograde menstruation from the endometrium.42, 43 Invasive mucinous ovarian 
cancers are metastases from the lower intestinal tract (e.g. stomach, colon, 
appendix) to the ovary.44 High-grade serous ovarian cancers are derived from the 
distal fallopian tubes.23, 45 A recent study demonstrated that ovulation, the release 
of hormones (e.g. estrogen and progesterone), growth factors, and inflammatory 
factors among others, promoted the migration of intrauterine-injected malignant 
cells towards the ovarian stromal compartment to form “ovarian” tumors.46 Thus, 
it is plausible that the unique hormonal milieu provided by functional ovaries 
serves to attract pre-malignant and malignant cells that may remain dormant (i.e. 
under progesterone concentrations) or fully progress to tumors (i.e. 
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postmenopausal contexts or upon loss of progesterone or functional PRs). 
Approximately 90% of ovarian cancers are detected in the ovary, with over 50% 
ovarian cancers diagnosed in post-menopausal women.47  
 
Figure 1-2: The cellular origins of ovarian cancer.  Ovarian cancer is a collective term 
for several distinct invasive diseases that originate in the peritoneal cavity. Inset, the 
known sites of origin associated with the major histopathological subtypes of ovarian 
cancer. Mucinous ovarian cancers are metastases on the ovary from the gastrointestinal 
tract, including the stomach, colon, or appendix. Endometrioid and clear cell ovarian 
cancers are derived either from the cervix or from the uterus via progression of 
endometriosis, which is linked to retrograde menstruation from the endometrium. 
High‐grade serous ovarian cancers are either derived from metastases from the distal 
fallopian tube or from the surface of the ovary. 
 
 Until recently, little was known about the relative distribution of PR within 
the subtypes of epithelial ovarian tumors. In a cohort of 504 tumors, we reported 
that 35% of ovarian tumors are PR-positive, with the highest total PR expression 
in endometrioid (67%) and serous (35%; low grade serous, 64%) subtypes.48 In 
accordance with our study, the international Ovarian Tumor Tissue Analysis 
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consortium examined the association of ER and PR expression with subtype-
specific survival in nearly 3,000 invasive epithelial ovarian tumors reporting 
positive total PR expression in endometrioid (67%), low-grade serous (57%), and 
high-grade serous (31%) tumors.49 Additionally, the study confirmed the 
prognostic significance of PR expression in ovarian tumors strongly expressing 
PR (≥50% tumor cell nuclei staining). Strong PR expression in high-grade serous 
ovarian carcinomas was associated with a significant improvement in survival; 
positive PR expression (weak or strong) in endometrioid carcinomas was 
associated with significantly improved disease-specific survival independent of 
patient age and tumor grade, site, and stage. Of note, ER expression conferred a 
patient survival advantage in endometrioid ovarian tumors only. ER may 
contribute to the favorable prognosis in endometrioid ovarian tumors via 
regulation of PR expression; a functional ER signaling pathway promotes robust 
PR expression.49 While total PR levels are routinely measured in breast and 
endometrial cancers (but rarely in ovarian cancer) for clinical management and 
disease treatment, very few studies have examined the levels of PR isoforms in 
ovarian tumors. To our knowledge, only three studies8-10 have reported 
differential expression of PR isoforms in ovarian tumors. These studies have 
reported a dominance of PR-B expression in ovarian tumors across all sub-types, 
with PR-B frequently expressed in the serous subtype. In contrast, PR-A 
expression was weakly expressed in mucinous and serous ovarian carcinomas 
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and comparison of normal to malignant ovarian tissues revealed reduced to 
absent expression in malignant tumors relative to PR-B.9 
1.5 Progesterone actions in ovarian cancer 
 The molecular mechanisms of progesterone’s protective role in ovarian 
cancer are not well understood; both proliferative and inhibitory actions of 
progesterone have been reported in ovarian cancer cell line models. Several 
independent in vitro studies demonstrated anti-proliferative actions of 
progesterone at higher concentrations (≥1 µM) in ovarian cancer cells, primarily 
through the induction of apoptosis50-53, while fewer studies reported progesterone 
as proliferative in these cells at lower concentrations.54, 55 The opposing cellular 
responses of ovarian cancer cells to progesterone may be attributed to cell 
context-dependent regulatory inputs to PR, such as progesterone dosing, kinase 
activation state of the cells, cofactor availability, or PR-A and PR-B expression 
ratios. Ovarian cancer cells are susceptible to concentration-dependent and 
biphasic effects within the same cell model systems. Similar to breast and uterus, 
crosstalk between PR and growth factor-mediated signaling pathways (i.e. 
protein kinases) presumably directs PR promoter selection and specific cell fates 
(e.g. apoptosis). The relative abundance of cofactors that associate with PR also 
varies in a tissue-specific manner.56, 57 As in other tissues (i.e breast and uterine), 
shifts in PR isoform ratios (PR-A and PR-B) and cofactor availability may 
contribute to variations in biological responses to progesterone. 
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 Taken together, these observations and findings serve as a strong 
rationale for defining progesterone receptor signaling as a strategy to inhibit the 
malignant transformation of ovarian epithelial cells and suppress ovarian cancer 
progression. The mechanisms responsible for mediating the tumor suppressive 
effects of progesterone in the ovaries are grossly understudied and therefore are 
not understood. Accordingly, the aims of these studies are the following: I) 
Determine the level of expression of PR isoforms in human ovarian primary 
tumors and in well-characterized cultured ovarian cancer cell lines, II) define the 
biological impact of PR expression and activity on ovarian cancer cell biology, 
and III) identify the post-translational modifications to PR and the cofactors 
required for mediating PR-dependent signaling actions.
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CHAPTER 2 
 
PROGESTERONE RECEPTORS INDUCE FOXO1-DEPENDENT 
SENESCENCE IN OVARIAN CANCER CELLS 
 
2.1 INTRODUCTION 
 
 Although ovarian cancer accounts for approximately 3% of all cancers 
among women, it is the deadliest among gynecologic cancers. An estimated 
15,500 deaths were expected in 201258, a death rate of more than 50% due to 
late detection of the disease and intrinsic or acquired resistance to current 
therapeutic strategies. The identification of reliable biomarkers for early detection 
of OC will have a substantial impact on survival rates, while molecular markers 
that predict outcome may allow for efficacious targeted therapies.  
 Progesterone receptors (PR) belong to the steroid receptor superfamily of 
related ligand-activated transcription factors that includes estrogen, androgen, 
mineralocorticoid, and glucocorticoid receptors.25 PR is a classical estrogen-
regulated ER-target gene. Two PR isoforms (full-length PR-B and N-terminally 
truncated PR-A) have been identified and characterized as ligand-activated 
transcription factors with distinct transcriptional activities, while a third (PR-C) 
modulates the other two in selected tissues.34, 59-62 Upon ligand binding, PR binds 
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directly to specific progesterone response elements (PREs) or tethers to other 
DNA-binding transcription factors to alter gene expression.25    
 PR has become an attractive target in OC. Progesterone deficiencies and 
a genetic loss of heterozygosity at the PR gene locus (Chr 11q23.3-24.3)63 are 
associated with increased OC risk. While elevated progesterone levels appear to 
play a protective role, multiparity and elevated circulating progesterone levels 
(10-fold) during pregnancy, as well as the suppression of ovulation, are 
associated with decreased OC risk.64 Similarly, the use of progestin-containing 
oral contraceptives is associated with decreasing lifetime risk of OC.65 The 
expression of PR is a favorable prognostic marker in ovarian tumors and 
associated with longer progression free survival.8, 11-18  
 PR transcriptional activity is commonly linked to the expression of many 
cell cycle regulators including members of the cyclin, cyclin-dependent kinase 
(CDK), and p21/p27 families.66 PR is often associated with survival and cell-cycle 
progression in breast and prostate cancer cells.38, 67, 68 Specifically, PR-B 
isoforms are more potent transcription factors in reporter gene assays and at 
selected PR target genes relative to PR-A isoforms, including genes that encode 
cell cycle regulators.34, 35 PR-B but not PR-A isoforms mediate mammary gland 
alveologenesis during normal breast development60 and induce cyclin D1-driven 
proliferation and pro-survival in breast cancer cells.69 Interestingly, however, a 
handful of reports have suggested that progesterone may inhibit these effects in 
ovarian cancer cells.50, 54, 55, 70-72 Of particular interest, is the association of PR-B 
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expression with the induction of cell-cycle arrest first observed in Ras-
transformed NIH3T3 cells73 and later extended to include OC cells.74 
Furthermore, expression of PR-B isoforms in ovarian tumors is associated with 
longer progression-free patient survival and an indicator of positive prognosis.8, 10 
Herein, the goal of our studies was to further investigate the impact of PR-B 
expression and activation on OC cell proliferation and to determine the signaling 
mechanisms responsible for PR-B-mediated cell-cycle control. 
 
2.2 MATERIALS AND METHODS 
Human Tissue Microarray and Immunohistochemistry 
 Tissue microarrays (TMA’s) were constructed as previously described75 
from representative tumor areas using a tissue arrayer (Beecher Instruments, 
Silver Spring, MD and Pathology Devices, Westminister, MD). Arrays were 
stained for PR (Ventana, #790-2223) and ER (LabVision, #RM9101S0). 
Immunohistochemistry was scored using a subjective assessment of percent 
positive cells in a TMA core where scores of ‘0’ = no positive cells, ‘1’ = > 0% but 
< 15%, ‘2’ = ≥ 15% but < 50%, and ‘3’ = ≥ 50%.  Recursive partitioning was used 
to determine the binarisation cutpoint for optimal separation of the five major sub-
types of ovarian carcinoma and resulted in raw scores of ‘0’ being considered 
negative (coded as ‘0’) and raw scores greater than ‘0’ being considered positive 
(coded as ‘1’). Contingency analysis was used to determine if there was 
differential expression of PR across the five major sub-types of ovarian 
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carcinoma, and the significance of those differences was determined by the 
Pearson Chi Square (Χ2) statistic. 
Cell Culture and stable cell line generation 
 All cell lines were grown at 37ºC under 5% CO2 in water-jacketed 
incubators (Forma Scientific, Asheville, NC). 1816-575 cells were kindly provided 
by Dr. Patricia Kruk (University of South Florida). HEY and ES-2 cells were kindly 
provided by Dr. Amy Skubitz (University of Minnesota). OVCAR-3 cells were 
kindly provided by Dr. Sundaram Ramakrishnan (University of Minnesota). 
OVCAR-8 cells were purchased from the DCTD Tumor/Cell Line Repository. 
PEO4 cells were kindly provided by Dr. Scott Kaufmann (Mayo Clinic). TOV-
112D were purchased from American Type Culture Collection. The T47D and 
T47D-YB breast cancer cell lines were maintained as described.76 The parental 
ES-2 ovarian cancer cell line was maintained as described.77 With the exception 
of the experiments performed on unstarved and untreated growing cell lines in 
Fig. 1, 24 hours prior to all experiments, cells were washed with PBS and placed 
in Modified IMEM supplemented with 5% charcoal-stripped FBS (i.e. DCC) 
(Hyclone, #SH30068.03). 
 Empty GFP-vector control and GFP-PR stable cell lines were generated 
using the parental ES-2 cell line as a model system. Stable cell lines were 
generated by transfecting cells with 2.0 µg of their respective plasmids using 
FuGene HD® transfection reagent (Roche, #04709691001) according to 
manufacturer’s instructions. After transfection, the cells were selected and 
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maintained with 0.5 mg/mL of G418 sulfate. The human PR-B gene was 
previously cloned into the pEGFP-N3 vector (Clontech Laboratories, Inc.), which 
also served as the Empty Control GFP vector.59 Fluorescence-activated cell 
sorting (FACS) with a FACSDiva™ cell sorter (BD Biosciences, San Jose, CA) 
was used to purify Empty GFP-vector control and GFP-PR-B containing stable 
cell lines by removing any low and non-GFP-expressing cells.  
 Stable shRNA expressing cell lines were created by transducing ES-2 
GFP-PR cells with pLKO.1 lentiviral vectors containing target gene shRNA 
sequences from the Open Biosystems Expression Arrest™ TRC Library (Thermo 
Scientific). shRNA cell colonies were selected in and maintained as described 
earlier with 1 µg/mL of puromycin. Stable control shRNA GFP-PR cells (sh-
control) were created using an empty vector (clone RHS4080) containing an 18 
bp non-targeting, non-specific “stuffer sequence”. Stably expressing p21 shRNA 
GFP-PR cells were created using a pLKO.1 lentiviral vector (clone 
TRCN0000010401), and FOXO1 shRNA GFP-PR cells were created using 
pooled pLKO.1 lentiviral vectors (clones TRCN0000039578 and 
TRCN0000039579). 
Primary Human Ovarian Cancer Cell Isolation  
 Cancerous human tissue samples were harvested at the time of surgery 
and immediately placed in 37°C PBS. Tissue samples were dissected into small 
pieces and placed in 6-well plates containing 0.25% trypsin-EDTA (1mM) 
(Invitrogen, #25200-056) for 3 hours at 37°C. Trypsinization was neutralized 1:1 
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with serum supplemented cell culture media and cells were allowed to plate 
overnight. The following day, partially digested tissue was removed and adherent 
cells were extensively washed with PBS before cell culture media was replaced. 
All tissue samples were typed and graded by in-house surgical pathologists. 
Reagents 
 Cells were treated with the following reagents (when applicable): R5020 
(Perkin Elmer, #NLP004005MG), RU486 (Sigma, #M8046), β-estradiol (Sigma, 
#E8875), and AS1842856 (EMD Millipore, # 344355). For experiments with 
AS1842856, cells were pretreated for one hour prior to the addition of R5020 in 
combination treatment studies. 
Immunoblotting 
 Western blots were performed as previously described.77 Western blots 
were probed using the following primary antibodies: PR-A/B (Ab-8, Fisher 
Scientific Lab Vision #MS298P) and PR (H-190) antibody (Santa Cruz 
Biotechnology, #sc-7208); full-length and cleaved-PARP (#9546), p21 (#2946), 
and FOXO1 (#2880) were purchased from Cell Signaling Technologies; and 
Actin (Sigma-Aldrich,  #A4700). Actin (Sigma, #A4700) and ERK (Cell Signaling 
Technologies, #9102) were used as loading controls where indicated. HRP-
conjugated goat anti-rabbit and goat anti-mouse (Bio-Rad, #170-6515 and #170-
6516) secondary antibodies were used to detect their respective primary 
antibodies, and immunoreactive proteins were visualized on Kodak X-OMAT LS 
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film (Carestream Health, #864-6770) following ECL detection with Super Signal® 
West Pico Maximum Sensitivity Substrate (Pierce, #34087). 
Real-Time Quantitative-PCR (RT-qPCR) 
 Total RNA was extracted from cell samples using TriPure Isolation 
Reagent (Roche, #11667165001) and isopropanol precipitation. RNA (1.0 µg) 
was reverse transcribed to cDNA according to manufacturer’s instructions using 
the qScript cDNA SuperMix (Quanta Biosciences, #95048-100). qPCR was 
performed using Light Cycler® FastStart DNA Master SYBR Green I (Roche, 
#12239264001) on a Light Cycler® 480 II Real-Time PCR System (Roche). 
Human primer sequences are listed in Supplementary Table 1. qPCR cycling 
conditions were as follows: initial denaturation at 95ºC for 10 min; denature at 
95ºC for 10 sec, anneal at 60ºC for 10 sec, and extension at 72º C for 5 sec for 
45 cycles. 
Luciferase Assays 
 Cells were co-transfected overnight using FuGene HD® transfection 
reagent (Roche) according to manufacturer’s instructions with 0.9 µg of either a 
PRE-containing34 or a p21 promoter-containing60 firefly luciferase reporter 
construct and 0.1 µg of a constitutively active pRL-TK-Renilla luciferase construct 
(Promega, #E2241). Luciferase assays were performed as previously 
described37 using the dual luciferase reporter assay (Promega, #E1910).  
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Histology and Microscopy 
 All brightfield and fluorescent cell images described herein were acquired 
with an Axioplan 2 upright microscope (Zeiss, Thorwood, NY) and captured using 
a SPOT camera (Diagnostic Instruments, Inc., Sterline Heights, MI) with the 
ProgRes Capture Pro software (Version 2.8.8) (Jenoptik Optical Systems Inc., 
Easthampton, MA). Cellular membranes were stained for 15 min at RT with 
Texas Red®-X-conjugated wheat germ agglutinin (1 µg/mL) (Invitrogen, # 
W21405), and all cell nuclei were stained with DAPI containing ProLong® Gold 
antifade reagent (Invitrogen, #P-36931). Fixed and live cell soft-agar images 
were acquired with a Leica DM IL inverted microscope (Leica Microsystems, Inc.) 
and captured using a MagnaFire® camera and MagnaFire® imaging software 
(Olympus, Melville, NY). 
Cell proliferation and survival assays 
 Cell proliferation was measured by using MTT assays as described 
previously.78 
 Anchorage-independent growth and survival were measured by using soft 
agar assays as previously described79 with the exception of seeding 2 X 104 
cells. After 4 weeks of growth at 37º C, cell colonies were stained with 0.1% 
crystal violet for 1 hr at RT and washed with PBS. 1,000 randomly chosen cell 
colonies per well were separated according to size (total pixels/colony area) and 
quantified using Photoshop® version 7.0 (Adobe Systems, Inc.). 
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Senescence Associated-β-galactosidase (SAβGal) Activity Assays 
 Cells were continuously treated for four days in 5% DCC. Cells were 
washed, fixed, and stained for SAβGal activity according to manufacturer’s 
instructions using the Senescence β-Galactosidase Staining Kit (Cell Signaling 
Technology, #9860).  
Flow Cytometry 
 Cells were treated in 5% DCC for 96 hrs. Cells were collected, fixed and 
stained as described previously.76 Propidium iodide staining was detected using 
a FACSCalibur (BD Biosciences). Cells were gated for cell cycle phases using 
FlowJo software (Tree Star Inc.). Cells were stained with 2 µg/mL of Hoechst 
33342 DNA-specific dye (Invitrogen, #H3570) and 0.5 µg/mL of Pyronin Y RNA-
specific dye (Polysciences, #18614-5). FACS analysis performed on a BDTM 
LSR II Flow Cytometer System (BD Biosciences) was used for cell-cycle analysis 
and separation of the G0 (Hoescht-low and Pyronin Y-low) and G1 (Hoescht-low 
and Pyronin Y-high) phases of the cell cycle as previously described.80  
Chromatin Immunoprecipitation (ChIP) 
 Cells were treated for 1 hr with either R5020 or ethanol vehicle in 5% DCC 
and cell samples were fixed, harvested, and lysed according to optimized 
manufacturer’s instructions using the ChIP-IT™ Express Magnetic Chromatin 
Immunoprecipitation Kit (Active Motif, #53008). Samples were homogenized 
using a Bioruptor sonicator (Diagenode, Inc.). ChIP reactions were incubated 
overnight on an end-to-end rotator using 95 µL of isolated chromatin and either 2 
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µg of PR-A/B antibody (Ab-8), FKHR (H-128) antibody (Santa Cruz 
Biotechnology, Inc., # sc-11350) or 0.4 µg of normal mouse or rabbit IgG (Santa 
Cruz Biotechnology, Inc., #sc-2025 # sc-2027). Samples were washed, eluted, 
reverse cross-linked, and treated with Proteinase K according to manufacturer’s 
instructions (Active Motif). DNA was analyzed by RT-qPCR as described above. 
Statistical Analysis  
 All reported values represent data representative of the indicated 
replicates of each experiment (mean ± the standard deviation (SD)). Statistical 
analyses were performed using a Student’s two-tailed t-test where significance 
was determined with 95% confidence (*p ≤ 0.05, **p ≤ 0.01). 
 
2.3 RESULTS 
PR expression in OC tumors and cell lines. 
 Studies of limited sample size report decreased or absent PR expression 
in human OC tissue samples and little information exists on the relative 
distribution of PR within OC subtypes.63 We evaluated the percentage of PR-
positive tumors from each major histological sub-type of ovarian surface 
epithelial (OSE) derived OC in a cohort of 504 tissue samples (Figure 1A). While 
percentages varied between sub-types, each group contained PR-positive 
tumors. PR expression was highest in endometrioid (67%) and serous (35%; low-
grade, 64%) tumors. Overall, 35% of ovarian tumors were PR-positive; a value 
consistent with larger mixed cohort studies.10, 16 The distribution of estrogen 
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receptor (ER)-positive tumors in the same cohort was similar to that of PR with 
endometrioid (77%) and serous (>70%) tumor sub-types displaying the highest 
portion of ER-positivity; the overall percentage of ER-positive tumors was 55%.   
 We next examined expression levels of PR in a panel of six established 
human OC cell lines of epithelial origin and one immortalized normal OSE cell 
line (1816-575). PR protein expression was low to negligible in all cell lines (data 
not shown), regardless of histologic sub-type (clear cell, ES-2; serous, HEY, 
OVCAR-3, OVCAR-8, PEO4; endometrioid, TOV-112D). Additionally, RT-qPCR 
analysis detected minimal levels of PR mRNA in each of these cell lines when 
compared to T47D human breast cancer cells (Figure 1B). Cell line models of 
human tumors frequently lose steroid hormone receptor expression when grown 
in tissue culture. Alternatively, estrogen responsiveness of the PR promoter may 
be diminished.81  
 To determine if ER-positive ovarian cancer cells are capable of inducing 
endogenous PR expression, PEO4 cells were treated with β-estradiol (E2, 1 nM) 
and PR mRNA and protein expression was evaluated (Figure 1C). E2 treatment 
of PEO4 cells significantly induced PR mRNA expression (4.3-fold) compared to 
vehicle treated controls. Untreated PEO4 cells contained low levels of PR-B 
protein. The expression of both PR isoforms (PR-A and PR-B) was significantly 
induced upon estrogen (E2) treatment relative to vehicle-treated and R5020-only, 
while R5020 treatment caused a slight up-shift in gel mobility of both PR-A and 
PR-B proteins in E2-treated cells (Figure 1D). The transcriptional activity of  
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Figure 2-1: PR is expressed in human ovarian cancer tissues and cancer cell lines.  
A) Immunohistochemical staining for PR in human ovarian cancer tissues representing 
the five major sub-types of ovarian surface epithelial (OSE) origin (n=504). B) RT-qPCR 
analysis of PR mRNA expression in a panel of six ovarian cancer cell lines and one 
immortalized, non-transformed cell line relative to PR+ T47D breast cancer cells. All 
values were normalized to GAPDH levels. C) RT-qPCR analysis of PR mRNA 
expression of PEO4 cells treated with vehicle (ethanol) or β-estradiol (E2, 1 nM) for 24 
hr (n=3, **p≤0.01). D) Western blot analysis of PR and ERα protein expression in PEO4 
cells treated with vehicle, R5020 (10 nM, 1 hr), E2 (1 nM, 48 hr), and E2 (1 nM, 48 hr) 
followed by R5020 (10 nM, 1 hr). T47D CO total cell lysate was loaded on the same gel 
as a positive control for PR expression. Total ERK was used as a loading control. E) 
Inset, Western blot analysis of PR expression in PEO4 cells treated with vehicle and 
R5020 (1 and 10 µM) for 48 hr. RT-qPCR analysis of SGK mRNA expression after 24 hr 
and 96 hr R5020 treatment (1 and 10 µM) in PEO4 cells (n=3, *p≤0.05, **p≤0.01). All 
values were normalized to GAPDH levels.  
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endogenous PR in PEO4 cells was evaluated in response to increasing doses of 
the PR-specific agonist, R5020, a synthetic progestin, at 24 and 96 hr. In the 
absence of estrogen, expression of the classic PR-target gene, 
serum/glucocorticoid regulated kinase (SGK)82, 83 was significantly induced by 
R5020 (10 mM) treatment relative to vehicle controls (Figure 1E), consistent with 
the modest up-shift in gel mobility of PR-B protein (Figure 1D inset). 
Pretreatment with estrogen did not further sensitize these cells to progestin (data 
not shown). These data suggest that OC cell lines express low abundance 
functional PR-B, as measured by the ability of progestins to induce PR-target 
gene (SGK) expression. 
Progestin induces non-proliferative cell survival in OC cells. 
 In order to investigate the impact of PR expression and signaling on OC 
cell biology without the confounding effects of exogenously added estrogen, we 
created a PR-expressing OC cell line. We chose ES-2 cells due to their 
inherently aggressive nature, rapid growth rate, ability to form tumors in 
xenograft84, 85, and low endogenous PR mRNA levels (Figure 1B). Notably, these 
cells are resistant to estrogen-induction of endogenous PRs (data not shown). 
ES-2 cells were transfected with GFP-tagged PR-B or GFP-only vectors, and 
PR+ clones were selected for PR protein expression levels that were comparable 
to similarly created T47D-YB breast cancer cells86 (Figure 2A inset). PR 
transcriptional activity in GFP-PR and control ES-2 cells was evaluated by PRE-
luciferase reporter assays. R5020 stimulated luciferase activity in GFP-PR cells, 
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Figure 2-2: Stable expression of PR in ES-2 cells increases cell survival and 
inhibits cell colony formation.  A) Inset, Western blot analysis showing stable 
expression of GFP-tagged PR-B in ES-2 cells (GFP-PR) as compared to parental ES-2 
cells stably expressing GFP-tagged empty vector construct (Empty control), and PR-B 
expressing T47D breast cancer cells (T47D-YB). ES-2 GFP-PR cells transiently 
transfected with a progesterone response element (PRE) containing luciferase reporter 
construct were treated for 48 hours with R5020 (10 nM) or RU486 (1 uM). Relative 
luciferase units (RLU) were normalized to the mean result ± standard deviation (SD) for 
Renilla luciferase expression (n=4, *p≤0.05). B) Inset, Western blot analysis of total and 
cleaved PARP in GFP-PR-containing ES-2 cells treated with R5020 for 4 days. Viable 
GFP-PR cells continuously treated with R5020 (10 nM) as measured by MTT assay (all 
values normalized to Day 0 readings, mean ± SD, n=3,  *p≤0.05). C) Empty control and 
GFP-PR expressing cells grown in soft-agar and stimulated with R5020 (10 nM) for 4 
weeks. Colonies were stained with crystal violet. D) Quantification of equal numbers of 
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colonies grown in soft-agar for 4 weeks (mean ± SD, n=3 fields/sample, 102 
colonies/field, *p≤0.05). Inset, Representative live-colony image taken at 100X 
magnification demonstrating the presence of viable, single- and two-cell colonies in 4-
week R5020 (10 nM) treated GFP-PR samples. 
 
but not in GFP-vector control cells; PR transcriptional activity was blocked by co-
treatment of the cells with the competitive PR antagonist RU486 (Figure 2A). 
Endogenous PR target genes (p21 and KLF4)28, 78 were similarly regulated in 
breast and ovarian cancer cells stably expressing PR-B (data not shown). 
Fluorescence microscopy indicated that GFP-PR-B accumulated in the nucleus 
upon R5020 stimulation (Figure 3).87 Interestingly, we observed an increase in 
the overall size of nuclei present within GFP-PR-B expressing cells exposed to 
R5020 for as little as 24 hours (Figure 3). 
 
 
Figure 2-3: Functional activity of stably expressed GFP-tagged PR in ES-2 ovarian 
cancer cells.  Immunofluorescence microscopy of Empty control and GFP-PR-
containing cells stimulated with vehicle (ethanol) control or R5020 (10 nM) for 24 hr. All 
images were acquired at 200X magnfication. 
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 Prior studies have shown that progesterone exhibits both proliferative54 
and anti-proliferative effects on the growth of OC cells51, 52, 88 with inhibitory 
effects observed at particularly high concentrations (≥ 10-6 M) of ligand.53-55 We 
investigated the effects of progestin on growth characteristics of GFP-PR ES-2 
cells. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) cell 
proliferation assays were initially utilized to study long-term effects of progestin 
treatment. GFP-PR and vector control cells were plated in equal numbers and 
stimulated with R5020 for 12 days. Measurements taken at 2-day intervals 
revealed an increase in growth, as measured by the number of viable cells 
expressing GFP-PR (treated or untreated with R5020) relative to vector-matched 
controls beginning at Day 2, with significantly increased growth at Days 4, 6, and 
8. By Day 8, cells containing GFP-PR treated with progestin significantly 
outnumbered vehicle-treated control cells expressing GFP-PR (Figure 2B). 
Interestingly, proliferation of ligand-stimulated cells expressing GFP-PR ceased 
by Day 8 and the number of viable cells present through day 12 remained 
unchanged. Cell numbers in all groups began to diminish at late time points, 
likely due to nutrient (i.e. in media) starvation. However, cells in the R5020-
treated cohort failed to die off in a predictable manner over a long period of time 
without media replenishment (Figure 2B). These findings suggest that PR may 
positively influence ovarian cancer cell number by promoting increased cell 
survival. We utilized poly (ADP)-ribose polymerase (PARP) cleavage as an 
indicator of apoptotic cell death. Beginning as early as Day 4, the amount of 
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cleaved-PARP was greater (2.7-fold) in vehicle-treated samples relative to 
R5020-treated samples, suggesting that PR activity inhibits apoptosis of GFP-PR 
cells (Figure 2B; inset). 
 To further examine the effects of liganded PR on OC cell survival and 
specifically, anchorage-independent growth, we performed soft agar colony 
formation assays where the constraints of 2-D growth and serum starvation are 
non-limiting over a four-week time course. When GFP-PR and vector-matched 
controls were either cultured with vehicle or R5020 for four weeks, R5020 
stimulation dramatically inhibited the formation of GFP-PR-containing cell 
colonies compared to GFP control cells (Figure 2C). Additionally, when an equal 
number of colonies were objectively sorted based on size by computer analysis, 
there were significantly more small colonies (0-25 pixels) and fewer large 
colonies (51-75 and 76-100 pixels) present in the ligand-stimulated group of 
GFP-PR-containing cells compared to vehicle controls (Figure 2D). After 4 weeks 
of soft-agar growth, single- and two-celled GFP-PR “colonies” or cell clusters 
remained viable but appeared dormant in the R5020-treated condition (Figure 
2D, inset). In sharp contrast, progestins induce pro-survival but are clearly 
mitogenic in PR-B+ breast cancer cells (MCF-7, T47D) grown in similar 
conditions.37, 79 
PR mediates OC cellular senescence. 
 Contrary to the pro-survival and pro-proliferative impact of progestins in 
breast cancer models, our data suggest that in the presence of progestin, PR-B 
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promotes a pro-survival but anti-proliferative phenotype in ES-2 OC cells. This 
paradoxical scenario where cells exist in a viable and metabolically active but 
non-proliferative state may be explained by the phenomenon of cellular 
senescence. The exit of proliferating cells from the cell-cycle (i.e. into G0) can be 
separated into a quiescent arm, where appropriately stimulated cells are capable 
of re-entering the cell-cycle, and a senescent arm that is classically defined as a 
state of permanent cell-cycle arrest.89 Therefore, we analyzed whether GFP-PR 
cells undergo a senescent transition following prolonged progestin exposure 
based on three criteria commonly used to identify cellular senescence: the 
expression of senescence-associated β-galactosidase (SAβGal), altered cell 
morphology, and cell cycle profiling.  
 The most common marker of cellular senescence is the accumulation of 
endogenous lysosomal beta-galactosidase, as measured by assay of 
senescence-associated beta-galactosidase (SAβGal) activity at pH 6.90 GFP-PR 
cells exposed to R5020 for four days significantly induced SAβGal (40%) relative 
to minimal SAβGal (10%) in empty vector and vehicle-treated cells, indicating 
senescence is induced in a ligand-dependent fashion specific to PR-positive cells 
(Figure 4A-B). We examined GFP-PR cells treated with R5020 (12 days) under 
high magnification (400X) for morphologic changes consistent with senescence 
(Figure 4C). SAβGal positive cells (white arrows) possessed enlarged nuclei and 
exhibited a wide, flattened appearance relative to SAβGal-negative cells in the 
same culture (asterisk).91 Finally, cell cycle analysis of GFP-PR cells by  
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Figure 2-4: PR expression and activity induces cellular senescence.   
A) Representative staining for SAβGal activity of Empty control and GFP-PR cells 
treated with R5020 (10 nM) for 96 hrs. (Magnification = 100X). Cell samples were 
mounted onto glass slides using ProLong® Gold Antifade Reagent with DAPI 
(Invitrogen) for brightfield microscopy. B) Percentage of positive SAβGal cells was 
determined from quantitating three fields at 100X magnification. Values were normalized 
to total nuclei present in each field from DAPI staining (n=3, **p≤0.01).  C) Exposure of 
ES-2 cells expressing GFP-PR to R5020 (10 nM) for 12 days induced cellular 
senescence as indicated by cells (arrowheads) with increased SAβGal activity, while 
non-senescent cells (asterisk) remain SAβGal negative. Senescent GFP-PR-containing 
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cells also develop a characteristically larger, more flattened morphology as revealed by 
TRITC-labeled wheat germ agglutinin (WGA-TRITC) cell membrane staining. Nuclei 
were identified by DAPI counterstaining. All images were acquired at 400X 
magnification. D) Cell cycle analysis by propidium iodide staining of GFP-PR-containing 
cells treated with R5020 (10 nM) for 96 hr (n=3, **p≤0.01). E) Flow cytometric analysis of 
DNA and RNA by Hoescht 33342 and Pyronin Y staining, respectively, of GFP-PR-
containing cells treated with R5020 (10 nM) (**p≤0.01). 
 
propidium iodide staining for DNA content demonstrated a significant increase in 
the percentage of cells in the G0/G1 phase accompanied with a decrease in the 
percentage of cells in the S phase of the cell cycle following four days of ligand 
exposure relative to vehicle controls (Fig. 4D). Quiescent cells, arrested in G0 
phase, have lower RNA content levels compared to transcriptionally active 
senescent cells in G1 phase.92 To further discriminate between G0 and G1 
populations from the combined G0/G1 compartment, we conducted differential 
staining of DNA (Hoescht 33342) and RNA (Pyronin-Y) prior to flow cytometry.80, 
93 We observed a significant decrease in the percentage of GFP-PR cells in G0 
phase relative to vehicle-treated cells, while the percentage of cells accumulating 
in the G1 phase was significantly increased (Fig. 4E). Taken together, these 
results suggest that OC cellular senescence occurs by a progestin and PR-B-
dependent pathway. 
Progestin-induced p21 expression mediates rapid OC cell senescence. 
 Cell cycle mediators are critical drivers of senescence.94 p21 is a well-
known cell-cycle inhibitor best characterized for its ability to prevent the transition 
from the G1 phase to the S phase by blocking cyclin E-CDK2 activity and to a 
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Figure 2-5: Progestins upregulate p21 expression to mediate cellular senescence.  
A) RT-qPCR analysis of p21 mRNA levels after 24 hr and 96 hr R5020 (10 nM) 
treatment in Empty control and GFP-PR-containing cells (n=3, **p≤0.01). B) Western 
blot analysis of p21 protein expression in Empty control and GFP-PR-containing cells 
after 8 days of R5020 (10 nM) treatment. C) ES-2 GFP-PR cells transiently transfected 
with a p21 promoter-containing luciferase reporter construct were treated for 24 hours 
with R5020 (10 nM) or RU486 (1 uM). Relative luciferase units (RLU) were normalized to 
the mean result ± standard deviation (SD) for Renilla luciferase expression (n=4, 
**p≤0.01). D) RT-qPCR analysis of p21 mRNA expression after 24 hr and 96 hr R5020 
(1 and 10 µM) treatment in PR+ PEO4 cells (n=3, *p≤0.05, **p≤0.01). E) Representative 
staining for SAβGal activity in PEO4 cells treated with R5020 (1 and 10 µM) for 96 hr. 
(Magnification = 100X). Cell samples were mounted onto glass slides using ProLong® 
Gold Antifade Reagent with DAPI (Invitrogen) for brightfield microscopy. F) Percentage 
of positive SAβGal cells was determine from quantitating three fields at 100X 
magnification. Values were normalized to total nuclei present per field from DAPI 
staining (n=3, *p≤0.05). 
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lesser extent cyclin A-CDK1/2 and cyclin B1-CDK1 activities.95 For this reason,  
increased p21 expression and activity have been directly linked to the induction 
of cellular senescence.96-98 Known PR target genes (p21, p15, p16, p27)34, 35, 78 
were examined in progestin-treated GFP-PR and control cells. Notably, in the 
presence of progestin, p21 exhibited significantly increased mRNA and protein 
expression (Figure 5A-B). Similar although somewhat blunted p21 induction was 
observed in R5020-treated PEO4 cells (Figure 5D). In addition, we observed 
increased p21 levels following up to eight days progestin treatment of primary 
isolates of PR+ OC cells (Figure 6B). p21 upregulation occurred at the level of 
transcription, as R5020 (24 hr) induced p21 promoter activity, as measured by 
luciferase reporter-gene assays; p21 transcriptional activity was blocked by co-
treatment of the cells with RU486 (Figure 5C). 
 Consistent with our results in ES-2 cells expressing GFP-PR, PR+ PEO4 
cells exhibited a significant increase in SAβGal following progestin exposure 
(Figure 5E-F). In addition, primary isolates of human OC cells expressing PR 
(Figure 6A) exhibited increased SAβGal activity following 10 days progestin-
treatment (Figure 6C). These data confirm that endogenously expressed PR 
drives senescence upon progestin stimulation of unmodified OC cells. 
 We next sought to determine whether progestin-induced senescence was 
dependent upon p21-induced cell cycle inhibition. We generated GFP-PR cells 
stably expressing p21-targeted shRNA (sh-p21) or a non-targeting vector control  
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Figure 2-6: Functional activity of stably expressed GFP-tagged PR in ES-2 ovarian 
cancer cells.  Immunofluorescence microscopy of Empty control and GFP-PR-
containing cells stimulated with vehicle (ethanol) control or R5020 (10 nM) for 24 hr. All 
images were acquired at 200X magnfication.  
 
(sh-control); p21 knockdown was confirmed by Western blotting (Figure 7A). We 
anticipated that p21 loss would block R5020-induced senescence. Surprisingly, 
we observed a significant increase in SAβGal activity and the development of a 
senescent phenotype after only four days of R5020 stimulation compared to sh-
control cells (Figure 7B-C). To account for the increase in SAβgal activity, we 
evaluated other senescence-associated cell cycle regulators, p15, p16, and p27 
in cells expressing sh-p21 (Figure 7D). Interestingly, upon R5020 (96 hr) 
treatment, p15 (23-fold), p16 (2-fold) and p27 (2-fold) mRNA levels were 
significantly induced in cells expressing sh-p21 relative to vehicle-treated cells or 
sh-controls. p21 expression was induced upon R5020 treatment in cells 
expressing either sh-control or sh-p21, although total expression was blunted 
following knock-down. These data suggest a mechanism for progestin-regulated 
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molecular compensation upon knock-down of p21 in cells expressing GFP-PR, 
and further implicate PR as a driver of cell cycle inhibition and, ultimately, cellular 
senescence in OC cells. 
 
Figure 2-7: High p21 expression is dispensable for PR-induced cellular 
senescence.  A) Western blot analysis of p21 expression after lentiviral infection of 
shRNA oligonucleotides containing a scramble, non-targeting sequence (sh-control) or 
p21-targeting sequence (sh-p21). Cells were treated with R5020 (10 nM) for 8 days after 
stable infection of shRNA oligonucleotides. B) Representative staining for SAβGal 
activity in cells expressing either sh-control or sh-p21 and treated with R5020 (10 nM) for 
96 hrs (magnification= 100X). Cell samples were mounted onto glass slides using 
ProLong® Gold Antifade Reagent with DAPI (Invitrogen) for brightfield microscopy. C) 
Percentage of positive SaβGal expressing cells was determined from quantitating three 
fields at 100X magnification. Values were normalized to total nuclei present from DAPI 
staining (n=3, *p≤0.05, **p≤0.01). D) RT-qPCR analysis of p15, p16, p21, and p27 
mRNA expression in the sh-p21 knockdown cells treated with R5020 (10 nM) for 96 hrs 
(n=3, *p<0.05, **p<0.01). 
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PR and FOXO1 cooperate to induce p21.  
 Previous studies identified FOXO1 as a PR target gene and master 
regulator of cell cycle mediators (p15, p16, p21, p27). Notably, FOXO1 and PR 
interact within transcription complexes in human endometrial stromal and cancer 
cells.99, 100 Like PR, FOXO1 expression is down-regulated in ovarian cancers.101 
FOXO1 mRNA and protein expression was significantly upregulated following 24 
hrs R5020 treatment (Figure 8A-B) and remained sustained for 96 hrs. Similar 
results were observed in progestin-treated PR+ PEO4 cells (data not shown). 
Chromatin immunoprecipitation (ChIP) assays revealed that upon R5020 
treatment (1 hr) of GFP-PR cells, PR was significantly recruited (18-fold) to a 
PRE-containing region downstream of the p21 transcriptional start site identified 
by PR ChIP-Seq studies conducted in breast cancer models102; PR recruitment in 
GFP-control cells was minimal and similar to background (IgG control) levels 
(Figure 8C). In contrast to the dramatic ligand-dependent recruitment of PR-B, 
FOXO1 was basally present within the same PRE-containing region in both 
control and GFP-PR cells; FOXO1 recruitment to this site was not significantly 
modulated in response to R5020 treatment. Cell fractionation experiments 
indicated that FOXO1 protein was nuclear in both the absence and presence of 
progestin (data not shown). 
 Since progestin treatment induces FOXO1 expression in PR-expressing 
cells, we next evaluated if FOXO1 was required for the induction of p15, p16, 
p27, and p21 in cells expressing sh-p21 shRNAs. To block the activity of FOXO1, 
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the selective small-molecular inhibitor, AS1842856 (AS), was utilized.103 Upon 
R5020 (96 hr) treatment, p15 (17-fold), p16 (2-fold), and p21 (18-fold), and p27 
(2-fold) mRNA levels were again significantly induced in cells expressing sh-p21  
 
Figure 2-8: Progestin treatment of GFP-PR-containing cells stimulates FOXO1 
expression and promotes PR recruitment to the p21 promoter.  A) RT-qPCR 
analysis of FOXO1 mRNA expression after 24 hr and 96 hr R5020 (10 nM) treatment of 
GFP-PR-containing cells (n=3, **p≤0.01). B) Western blot analysis of FOXO1 expression 
in response to 96 hr of R5020 (10 nM) treatment in GFP-PR-containing cells. C) RT-
qPCR analysis of PR and FOXO1 recruitment to p21. Empty control and GFP-PR 
expressing cells were stimulated with vehicle or R5020 (10 nM) for 1 hr. Fixed lysates 
were chromatin immunoprecipated with antibodies to PR or FOXO1 and qRT-PCR was 
performed on isolated DNA. D) RT-qPCR analysis of p15, p16, p21, and p27 mRNA 
expression in sh-p21 knockdown cells treated with R5020 (10 nM), FOXO1 inhibitor, 
AS1842856 (AS) (50 and 100 nM), or the combination of AS1842856 and R5020 for 96 
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hrs (n=2, *p<0.05, **p<0.01). E) Western blot analysis of FOXO1 expression in cells 
expressing sh-p21 after treatment with vehicle, R5020 (10 nM), AS1842856 (50 and 100 
nM), or the combination of AS1842856 and R5020 for 96 hrs. F) Representative staining 
for SAβGal activity of sh-p21 knock-down cells treated with R5020 (10 nM), AS1842856 
(AS, 100 nM), or the combination of AS1842856 and R5020 for 96 hrs. (Magnification = 
100X). Cell samples were mounted onto glass slides using ProLong® Gold Antifade 
Reagent with DAPI (Invitrogen) for brightfield microscopy. G) Percentage of positive 
SAβGal cells was determined from quantitating three fields at 100X magnification. 
Values were normalized to total nuclei present in each field from DAPI staining (n=2, 
**p≤0.01). 
 
relative to vehicle-treated cells (Figure 8D). Treatment with AS (50 or 100 nM) 
alone did not affect basal (vehicle) mRNA levels. However, the addition of AS to 
R5020-treated cells significantly blunted induction of p15, p16, p21, and p27, 
indicating that FOXO1 activity is required for progestin-induced expression of 
these cell cycle regulators. Furthermore, AS blocked basal and progestin-
induced FOXO1 protein expression in cells expressing sh-p21 (Figure 8E). 
Importantly, AS treatment had no effect on GFP-PR-B expression (Figure 8E). 
Moreover, progestin-induced senescence, as measured by SAβGal activity, was 
significantly reduced upon inhibition of FOXO1 (i.e. in the presence of AS) 
relative to R5020-treated controls (Figure 8F-G). Together, these data implicate 
FOXO1 as a key mediator of cell cycle gene expression associated with 
progestin-induced ovarian cancer cell senescence. 
FOXO1 expression is required for PR-induced senescence in OC cells. 
 Our data suggest that in the presence of progestin, liganded PR may 
primarily tether to pre-existing FOXO1 (i.e. located at nearby or distant sites) in 
order to facilitate hormone-regulated expression of p21 and senescence 
induction. A similar paradigm has been defined for ER tethering to FOXA1 
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pioneer factors in breast cancer models.104 To test the FOXO1-dependence of 
PR-induced senescence, we generated GFP-PR cells stably expressing FOXO1- 
 
Figure 2-9: PR-induced cellular senescence is dependent on FOXO1 expression. 
A) Western blot showing FOXO1 expression in cells expressing either sh-control or sh-
FOXO1 after treatment of R5020 (10 nM) for 96 hr. B) RT-qPCR analysis of p21 mRNA 
expression in sh-control and sh-FOXO1-containing cells after 96 hr of R5020 (10 nM) 
treatment (n=3, **p≤0.01). C) Cell cycle analysis by propidium iodide staining of cells 
expressing either sh-control or sh-FOXO1 and stimulated with R5020 for 96 hrs. (n=3, 
**p≤0.01). D) RT-qPCR analysis of PR recruitement to p21. Sh-control and sh-FOXO1-
containing cells were stimulated with vehicle or R5020 (10 nM) for 1 hr. Fixed lysates 
were chromatin immunoprecipated with an antibody to PR and qRT-PCR was performed 
on isolated DNA. E) Representative staining of SAβGal activity of sh-control and sh-
FOXO1-containing cells after treatment of R5020 for 96 hrs. Cell samples were mounted 
onto glass slides using ProLong® Gold Antifade Reagent with DAPI (Invitrogen) for 
brightfield microscopy. F) Percentage of positive SAβGal cells was determine from 
quantitating three fields at 100X magnification. Values were normalized to total nuclei 
present from DAPI staining. (n=3, **p≤0.01). 
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targeted shRNAs (sh-FOXO1); FOXO1 knockdown was confirmed by Western 
blotting (Figure 9A). Interestingly, PR expression also diminished slightly in cells 
stably expressing sh-FOXO1; some loss of PR occurred in multiple clones and 
using distinct FOXO1-targeted shRNAs (not shown), suggesting a mechanism for 
co-expression of these “coupled” factors. Early passage clones expressing sh-
FOXO1 that retained significant PR expression were used for further study. As 
expected, p21 mRNA levels were greatly diminished in cells expressing sh-
FOXO1 relative to sh-controls in both vehicle and R5020-treated conditions 
(Figure 9B). Similarly, R5020 treatment did not induce p15, p16, or p27 mRNA 
expression in cells expressing sh-FOXO1 (Figure 10).  
 
Figure 2-10:  RT-qPCR analysis of p15, p16, and p27 mRNA expression in PR+ cells 
expressing sh-control or sh-FOXO1 after treatment of R5020 (10 nM) for 96 hrs (n=3). 
 
 In addition, PR recruitment to the PRE-containing region located 
downstream of the p21 transcriptional start site was also similarly reduced in 
cells expressing sh-FOXO1 relative to controls, as measured by ChIP assays 
(7.7-fold vs. 12.1 fold) (Figure 9D). To confirm that diminished transcriptional 
regulation of p21 was not entirely due to reduced levels of PR protein observed 
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in cells expressing sh-FOXO1 (Figure 9A), we performed qRT-PCR analysis of 
additional PR-target genes; R5020 treatment (24 hrs) of ES-2 GFP-PR cells 
stably expressing sh-FOXO1 resulted in significant upregulation of a number of 
PR-target genes, including HSD11B2, KLF4, and NET1 (Figure 11).  
 
Figure 2-11:  RT-qPCR analysis of HSD11B2, KLF4, and NET1 mRNA expression in 
the PR+ cell expressing sh-FOXO1 after treatment of R5020 (10 nM) for 24 hrs (n=3, 
*p≤0.05, **p≤0.01). 
 
 Consistent with loss of progestin-induced p21 expression, R5020 
treatment failed to induce G0/G1 cell cycle arrest up to 96 hrs in cells expressing 
sh-FOXO1 cells relative to sh-controls (Figure 9C). Interestingly, the percentage 
of cells in S phase was enhanced upon knock-down of FOXO1 in both vehicle 
and R5020-treated PR-B+ cells when compared to sh-controls. Consistent with 
these results, progestin-induced SAβGal activity was also significantly reduced 
when FOXO1 was stably down-regulated relative to sh-controls (Figure 9E-F). 
 Overall, these data are consistent with a model in which PR-expressing 
OC cells induce FOXO1-dependent p21 expression in the presence of 
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progestins. FOXO1 is a required factor for PR-induced p21 expression and 
cellular senescence (Figure 12). 
 
Figure 2-12: Proposed model of PR-induced cellular senescence in ovarian cancer 
cells.  Progestin treatment of PR-expressing OC cells induces expression of p21 and 
FOXO1. PR and FOXO1 cooperatively upregulate p21 expression to promote cellular 
senescence. In the absence of p21, PR induces numerous FOXO1 target genes that 
compensate as mediators of senescence. 
 
2.4 DISCUSSION 
 Progesterone is a potent breast mitogen, but functions to inhibit 
proliferation in the uterus. Indeed, PR action is highly context-dependent and 
heavily influenced by post-translational modifications105 as well as cofactor 
availability.106 The detailed molecular mechanisms of progesterone’s protective 
role in ovarian cancer are not well understood; both proliferative and inhibitory 
actions of progesterone have been reported50-53, including concentration-
dependent biphasic effects within the same model system.54 This is perhaps in 
part due to the complexity of progesterone action. Numerous progesterone 
receptors exist (PR-A, PR-B, PR-C, mPRa, mPRb, mPRg, and PGRMC1) and 
their activities and potential interactions are still poorly defined.77 In this study, we 
demonstrated that nuclear PR-B receptors exhibit ligand-dependent anti-
proliferative effects by inducing cellular senescence in OC models.  
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 Several independent in vitro studies have demonstrated the inhibitory 
action of progesterone on OC cell growth, primarily through the induction of 
apoptosis51-55, 88, while other studies report progesterone’s proliferative actions.54 
The opposing cellular responses of progesterone’s effects in normal and 
malignant ovarian surface epithelial cells may be attributed to dosage effects: 
mitogenic effects were observed at low progesterone concentrations (<10-8 M) 
while growth inhibition and apoptosis were associated with high progesterone 
concentrations (≥10-6 M).63 Alternatively, opposing effects of progesterone may 
be attributed to the presence of two isoforms of the nuclear receptor (PR-A and 
PR-B).106 Several in vitro studies have demonstrated PR-A to be inhibitory of the 
transcriptional activity of PR-B, as well as other nuclear receptors, including 
glucocorticoid, mineralcorticoid, androgen, and estrogen receptors.106 PR-B is a 
more potent transcription factor relative to PR-A in gene array studies, but these 
receptors also regulate overlapping, but distinct gene subsets34 that are also 
tissue-specific. Our studies identify ligand-activated PR-B as a mediator of OC 
senescence.  Notably, progesterone can bind to members of the membrane 
progesterone receptor family, mPRα (PAQR7), mPRβ (PAQR8), mPRγ (PAQR5), 
and progesterone receptor membrane component-1 (PGRMC1) with varying 
responses that are likely also tissue-specific and context-dependent.107 Namely, 
PAQR have been shown to weakly activate the JNK1/2 MAPK pathway and 
induce JNK-dependent BAX mRNA expression in ovarian cancer cells77. These 
receptors also rapidly activate p42/p44 MAPKs in breast cancer cells.108 
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However, the primary signaling mechanisms and associated physiological 
functions of these receptors remain incompletely understood. PAQR bind 
progesterone with relatively high affinity and do not recognize the synthetic 
progestin, R5020, or the nuclear PR antagonist, RU486.109 In addition to PR-null 
cell controls, our studies used R5020 (10 nM) in order to avoid activating 
unrelated but ubiquitous membrane progesterone receptors (i.e. PAQR family 
members) present in OC cells.77 Interestingly, PR+ PEO4 cells required at least 
10 mM progestin for appreciable activation of endogenous PR-B (Figure 1E 
inset), as measured by gel mobility up-shift of PR-B and regulation of well-
characterized PR target genes (SGK). Subtle up-shift in PR gel mobility is 
indicative of direct global PR phosphorylation, modifications that augment PR 
nuclear localization and enhance transcriptional activity at selected promoters.105, 
110 The basis of these concentration effects is unknown; the concentrations used 
in the PEO4 cell model are similar to physiological levels within the 
microenvironment of the ovary (≥ 1 µM).53, 111 However, ovarian cancer cells may 
lack the so-called non-genomic or “rapid” signaling events that are integrated 
with ER-alpha and PR-B transcriptional activities in response to hormones and 
are well-characterized in breast cancer models.112, 113 
 Indeed, protein kinases are vital regulatory inputs to steroid hormone 
receptor action.114 Takahashi and colleagues characterized cAMP-induced 
senescence in SKOV ovarian cancer cells overexpressing PR-B and observed 
induction of both p21 and p27 expression.74 Although these authors did not 
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pursue the mechanisms of these effects, cAMP, via the actions of cAMP-
dependent protein kinases and/or activation of Ca++ channels115, may induce 
changes in PR-B phosphorylation that alter ligand-binding and/or co-factor 
interactions.116 Interestingly, cAMP has been demonstrated to regulate the cell 
cycle in cancer cells117 as well as induce and/or activate a variety of transcription 
factors such as STAT5, C/EBPβ, and FOXO1, all proteins that directly interact 
with PR.118-120 As such, cAMP may lower the requirement for PR ligand-binding 
and/or tethering to FOXO1 at PR target genes. We detected little to no change in 
cAMP accumulation following a time course of progesterone or R5020-treatment 
of OC models.77  
 Our study demonstrates a detailed molecular mechanism whereby 
progestins activate nuclear PR-B to upregulate FOXO1 expression leading to 
robust induction of cell cycle mediators of senescence. In this case, p21 
expression required both liganded PR-B and expression of FOXO1. Notably, 
progestin treatment of OC cells expressing sh-p21 promoted a significantly 
increased senescence response relative to sh-controls. Interestingly, in the 
context of diminished p21, hormone-bound PR significantly induced other well-
characterized pro-senescence effectors that are also FOXO1 target genes, such 
as p15, p16, and p27. These PR signaling alternatives reveal FOXO1-dependent 
tumor suppressive or “fail-safe” mechanisms, which may ensure that senescence 
occurs in the face of impaired p21. Deregulation of FOXO1 is associated with 
tumorigenesis and cancer progression. FOXO1 is downregulated in several 
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carcinomas, including ovarian101, through alterations in upstream regulators (i.e. 
inactivating mutations to PTEN, active PI3K-AKT signaling), post-translational 
deregulation, or by genetic mutations.121 The targeted re-expression and 
activation of FOXO1 using chemical and/or biological therapeutic strategies may 
overcome resistance or sensitize cancer cells to current therapeutics. Ultimately, 
our studies showed that OC senescence is dependent and specific to both PR-B 
and FOXO1; the ablation of FOXO1 (a PR target gene) significantly diminished 
the emergence of progestin-induced p21 expression and cellular senescence. 
Linkage of PR and FOXO1 signaling has been reported in the uterus122. Notably, 
these molecules trend towards co-occurrence in 570 samples analyzed from The 
Cancer Genome Atlas (TCGA) ovarian serous cystadenocarcinoma provisional 
data set (p= 0.209, Fisher’s exact test, odds ratio (OR) = 2.14, 95% confidence 
interval: 0.59-7.73)123, suggestive that numerous PR-target genes may be 
sensitive to FOXO1 expression.  
In contrast to our finding that PR-B is a mediator of OC senescence, the 
same receptor, when expressed in breast cancer cells, is clearly mitogenic.25 The 
opposing biology in ovarian versus breast cancer cells may be largely dependent 
on cell context. Studies in T47D breast cancer cells growing in 2D culture 
conditions demonstrated biphasic effects of progestin on cell cycle 
progression.124-126 Early effects of progestin treatment are proliferative as T47D-
YB cells accelerate through one or more mitotic cycles; cells are growth inhibited 
at late time points coincident with induction of p21 and p27. A secondary 
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progestin treatment failed to restore cell cycle progression although PR levels 
remained high. Interestingly, epidermal growth factor (EGF) restored progestin-
stimulated proliferation and prevented cell cycle arrest. In contrast to studies 
conducted in 2D culture systems, progestin is clearly mitogenic and a mediator of 
pro-survival and proliferation in breast cancer cells (T47D, MCF-7) cultured in 
anchorage independent (soft agar) conditions. The paradoxical effects of 
progestins observed in breast relative to ovarian cancer cells may be attributed to 
differential cross-talk between PR and growth factor-mediated signaling 
pathways, differential regulation of PR itself via post-translational modifications, 
and/or differential recruitment of required co-factors, such as FOXO1. Related to 
these studies, forkhead family transcription factors such as FOXO1 and FOXA1 
are negatively regulated by phosphorylation events. AKT-dependent 
phosphorylation prevents their nuclear accumulation and thus impairs target 
gene regulation.121 As mutations of PI3Ks or PTEN are common events 
(particularly in breast127 and ovarian cancers41, 128), activated AKT may prevent 
PR-induced senescence signaling by nuclear exclusion of FOXO1 partners or 
pioneer factors.  
 To date, the use of progestins, megestrol acetate and medroxy-
progesterone acetate, as OC therapies have been evaluated in a total of 14 
relatively small phase II clinical trials with variable inclusion criteria and modest 
response rates.129 Data from these trials support the concept that endometrioid 
and serous ovarian cancers are frequently sensitive to hormones and thus more 
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likely to respond to endocrine therapy.129 To optimize response rates, the 
identification of PR-B as a biomarker within ovarian tumors may be 
advantageous prior to therapy. Genetic loss of heterozygosity of the PR gene 
(ch. 11q23.3-24.3) occurs in approximately 75% of ovarian tumors.130, 131 
Alternatively, when the PR gene locus is intact, it may be possible to restore PR 
expression in PR-low or null OC. For example, robust isoform-specific re-
expression of PR has been demonstrated using activating duplex RNAs that 
target promoter regions in DNA; these reagents are currently in development for 
therapeutic use.132  
 In sum, our studies suggest that activation of nuclear PR-B may provide a 
means to force ovarian cancer cells out of the cell cycle and into a form of 
irreversible “stasis” by inducing cellular senescence. A clear understanding of the 
mechanisms and mediators of cellular senescence is highly relevant to modern 
cancer therapy, as the specific targeting of the senescence pathway in tumor 
cells is predicted to impede tumor progression to advanced and metastatic 
disease.133 Senescent cells cannot further divide, but depend upon selected 
signal transduction pathways for prolonged survival, and thus may be more 
vulnerable to subsequent therapies that target these survival pathways (i.e. 
senescence creates a form of synthetic lethality). Thus, the induction of PR-
mediated cellular senescence via progestin therapy may provide a safe and 
useful strategy to limit uncontrolled proliferation of ovarian cancer cells. In 
particular, translation of these findings may open the way for combination 
  48 
therapies that couple PR-dependent senescence induction with targeted 
therapies aimed at blocking cell survival pathways, including AKT signaling. Such 
“rational targeting” strategies can minimize treatment-related morbidity and may 
be necessary in order to achieve significant improvements in overall OC patient 
survival.  
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CHAPTER 3 
 
FOXO1 IS A KEY DETERMINANT OF PROGESTERONE RECEPTOR 
ISOFORM-SPECIFIC SENESCENCE PROGRAMMING  
IN OVARIAN CANCER CELLS 
 
 
3.1 INTRODUCTION 
 
 Approximately 1.3% of women will be diagnosed with ovarian cancer in 
their lifetime.134 Increased ovarian cancer risk is associated with progesterone 
deficiencies during infertility or with increasing age, and may occur as the result 
of genetic loss of heterozygosity at the progesterone receptor (PR) gene locus.4, 5 
Conversely, elevated progesterone levels experienced during pregnancy 
transiently and reversibly increase breast cancer risk135, but significantly reduce 
ovarian cancer risk in Asian, European, and North American populations.6 
Consistent with these findings, use of hormonal contraceptives (that include a 
progestin) is associated with increased risk of breast cancer136-139 but reduced 
risk of ovarian cancer.7, 139, 140 During ovulation the release of a mature follicle 
into the fallopian tube space requires shedding of ovarian epithelial cell layers 
followed by local proliferation that is analogous to wound repair. High levels of 
progesterone experienced during pregnancy or during the luteal phase of the 
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normal menstrual cycle prevent follicle development. Thus, progesterone is 
believed to exert its protective effect on ovarian cancer in part by reducing the 
number of times ovulation occurs (i.e. via fewer cycles of ovulation-associated 
“damage and repair”).  
Similar to PR expression in luminal (estrogen receptor (ER)-positive) 
breast tumors, PR expression in ovarian tumors is a favorable prognostic marker 
associated with longer progression-free survival.8, 11-18 Roughly 35% of ovarian 
tumors express PR; PR expression is highest in the endometrioid (67%) and 
serous (35%) sub-types.48, 49 Full-length PR-B and N-terminally truncated PR-A (-
164 amino acids) isoforms are encoded by the same gene and mRNAs. PR 
isoforms are ligand-activated transcription factors with distinct transcriptional 
activities. Following ligand binding, PRs dimerize (A:A, B:B, and A:B) and are 
retained in the nucleus where they repress or activate transcription of PR-target 
genes, either directly through binding to progesterone response elements (PREs) 
on chromatin, or indirectly via tethering interactions with other transcription 
factors (e.g. AP1, SP1, STATs, FOXO).27, 29, 30, 141 
 Studies of isoform-specific knockout mice determined that PR-B is 
required for mammary gland development, while PR-A is required for uterine 
development and reproductive actions.1, 60, 142, 143 While PR-A and PR-B share 
structural and sequence identity downstream of the BUS (B-upstream segment), 
they are unique transcriptional regulators of distinct gene sets.34 Little is known 
about how PR isoform-specific transcription is regulated in PR-expressing tissues 
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and tumors; total PR rather than PR isoform expression is measured clinically. 
Progesterone and progestins, acting through PR-B, are proliferative in the 
breast.69 However, in the endometrium of the uterus, paracrine signals secreted 
from PR-A-containing stromal cells antagonize estrogen-induced epithelial 
hyperplasia.60 
 Our previous study48 demonstrated that ligand-activated PR-B induces 
cellular senescence via induction of known cellular senescence mediators, 
including p21 and p15 via a FOXO1-dependent mechanism in ovarian cancer 
cells. FOXO1 interacts with steroid hormone receptors (SRs), including the 
androgen receptor (AR)144, 145, ER alpha (ERα)146, and both PR isoforms, PR-A 
and PR-B.120, 147 PR-B and FOXO1 were co-recruited to the same PRE-
containing region of the p21 upstream promoter. Both proteins were required to 
activate p21 expression; stable knockdown of FOXO1 or inhibition of FOXO1 
activity using the small molecule inhibitor AS1842856 blunted progestin-induced 
p21 expression in PR-B-expressing cells and blocked PR-dependent cellular 
senescence.  
 PR isoform-specific actions have not been studied in ovarian cancer 
models. In vitro studies primarily performed in breast or uterine cancer models 
have demonstrated PR-A trans-repression of PR-B, as well as other SRs, 
including AR and ERα.106 Notably, PR-A expression is markedly reduced relative 
to PR-B in ovarian tumors.8-10 To study PR isoform-specific gene regulation and 
biological consequences, we engineered ovarian cancer (ES-2) cells to stably 
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express either empty vector (control), PR-A-only, or PR-B-only. Our studies 
indicate that PR-B is the dominant driver of cellular senescence in ovarian cancer 
cells and reveal a novel mechanism of regulation of hormone sensitivity via PR 
isoform-specific target gene expression; the presence or absence of activated 
FOXO1 confers potent PR-B-like transcriptional activity to PR-A. A clear 
understanding of PR isoform-specific actions and their co-regulators may reveal 
novel ways to pharmacologically select for PR-driven inhibitory over proliferative 
actions in hormone driven cancers. 
 
3.2 MATERIALS AND METHODS 
Cell Culture and stable cell line generation 
 The human PR-B gene was previously cloned into the pEGFP-N3 vector 
(Clontech Laboratories, Inc.), which also served as the Empty Vector (EV) control 
vector.48, 87 GFP-tagged EV control, PR-A, and PR-B (with the isoform A start site 
mutated to Ala) stable clonal cell lines were generated using the parental ES-2 
cell line as a model system. Stable cell lines were generated by transfecting cells 
with 2 µg of their respective plasmids using FuGene HD® transfection reagent 
(Roche, #04709691001) according to manufacturer’s instructions. Twenty-four 
hours post-transfection, cells were selected and maintained with McCoy’s 5A 
Modified medium supplemented with 10% charcoal-stripped fetal bovine serum 
(i.e. DCC) (Hyclone, #SH30068.03), 100 units/mL penicillin, 100 µg/mL 
streptomycin, and 0.5 mg/mL of G418 sulfate (Corning, #61-234-RG). 
Fluorescence-activated cell sorting (FACS) with a FACSAria II cell sorter (BD 
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Biosciences) was used to purify GFP+ EV, PR-A-, and PR-B-containing cells by 
removing any low and non-GFP-expressing cells. Clones were then established 
and cultured from the FACS-purified population.  
 Stable FOXO1 expression cells were generated by infecting ES-2 PR-A-
expressing cells (clone #1, #5) with the retroviral pBabe puro L vector (which also 
served as the EV control) containing the constitutively active FOXO1 (FOXO1-
AAA).148 The pBabe puroL HA FKHR AAA plasmid was a gift from William 
Sellers (Addgene #9025). Cells were selected in and maintained as described 
earlier with 1 µg/mL of puromycin.48  
Ex vivo culture of human ovarian tumors 
 Ovarian cancer tissues were provided by the University of Minnesota 
Biological Materials Procurement Network (BioNet). All de-identified tissue 
samples received in this study were obtained with written informed consent in 
accordance with the University of Minnesota Institutional Review Board under 
exemption status. 
 Dissection, plating, and treatments of ovarian cancer tissue were 
performed as described previously,149-151 with a few exceptions. After surgical 
excision and pathological examination, fresh ovarian cancerous tissue was 
placed in 10 mL of McCoy’s 5A medium supplemented with 5% DCC for 
transport back to the laboratory. Tissue was dissected into 1-mm3 pieces and 
cultured in duplicate wells containing presoaked gelatin sponges (Ethicon, Inc., 
#1969) in 12-well plates containing 1.5 mL explant media (McCoy’s 5A medium 
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supplemented with 10% DCC, hydrocortisone (0.01 mg/mL), and insulin (0.01 
mg/mL)) within one hour of receiving tissue from BioNet. Tissue cultures were 
placed in a 37°C incubator with 5% CO2 for 24 hr. Afterwards, media was gently 
aspirated from each well. 1.5 mL explant media containing 10 nM R5020 or equal 
volume vehicle (ethanol) was added to corresponding treatment wells and placed 
in a 37°C incubator with 5% CO2. To equilibrate the sponges with hormone 
treatments, media was gently aspirated every 1 hr and replenished with fresh 
explant media containing 10 nM R5020 or equal volume vehicle (ethanol) for a 
total three times. Plates were returned to a 37°C incubator with 5% CO2 for 48 hr. 
Afterwards, tissues were gently removed from the sponges with sterile forceps 
and processed for RNA or protein isolation as described below. 
Reagents 
 Cells were treated with the following reagents (when applicable): R5020 
(Perkin Elmer, #NLP004005MG) and AS1842856 (EMD Millipore, #344355). For 
experiments with AS1842856, cells were pretreated for one hour prior to the 
addition of R5020 in combination treatment studies. 
Luciferase assays 
 Cells were cotransfected overnight using FuGene HD® transfection 
reagent (Roche) according to manufacturer’s instructions with either 0.5 µg of a 
PRE-containing34 (2X-PRE) firefly luciferase reporter construct, 1 µg of a p21 
promoter-containing firefly luciferase reporter construct48, or 4 µg (for p21 
promoter-luciferase assay) or 0.5 µg (for RT-qPCR analysis of endogenous 
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genes in PR-B cells) of GFP-tagged N3-PRA vector. The constitutively active 
pRL-TK-Renilla luciferase construct (Promega, #E2241) (10 ng) was 
cotransfected as a transfection control. Luciferase assays were performed as 
previously described48 using the dual luciferase reporter assay (Promega, 
#E1910).  
 In experiments using HeLa cells, 10 ng of GFP-tagged EV or PR-A vector, 
10 ng pcDNA3 empty vector (pc-EV) or Flag FKHR152 (pc-FOXO1 WT), 0.5 µg of 
a PRE-containing34 (2X-PRE) firefly luciferase reporter construct, and 10 ng of a 
constitutively active pRL-TK-Renilla luciferase construct (Promega, #E2241) 
were transiently cotransfected. pcDNA3 Flag FKHR was a gift from Kunliang 
Guan (Addgene plasmid # 13507). 
Gene expression profiling 
 Clonal ES-2 cells stably expressing GFP-tagged EV (clone #3), PR-A 
(clone #7), and PR-B (clone #1) and breast cancer cells T47D Y, YA, and YB 
originally described by Sartorius et al86 were hormonally starved in modified 
improved MEM (IMEM) (Gibco, catalog #A10488) plus 5% DCC for 24 hr. 
Afterwards, cells were treated with R5020 (10 nM) or vehicle control for 24 hour 
prior to RNA extraction using the RNeasy kit (QIAgen, #74104). DNase I treated 
(QIAgen, #79254) triplicate RNA samples were prepared for expression analysis 
using the Illumina HT-12v4 bead chip platform according to the manufacture’s 
protocols. Data were analyzed within R software153 using the Bioconductor154 
package, lumi155 where raw intensities were log2 transformed and quantile 
  56 
normalized. Differentially expressed genes were analyzed using the limma 
package156, where empirical Bayes was used to better estimate the variance of 
the genes. Gene expression data presented contain log2 normalized intensities 
and biological comparisons presented (e.g. R5020/vehicle) contain log2 fold 
change with the Benjamini and Hochberg (BH) adjusted P value.157 Heat maps 
were generated by unsupervised hierarchical clustering of genes via the 
‘aheatmap’ function in the NMF R package.158 Clustering was performed using 
Pearson distance and average linkage. Rows were scaled to have mean zero 
and standard deviation equal to one. All gene expression data is available in the 
NCBI Gene Expression Omnibus (GEO) database (accession number: 
GSE69296). 
Real-time quantitative PCR (RT-qPCR) 
 Total RNA was extracted from cells in triplicate wells using TriPure 
Isolation Reagent (Roche, #11667165001) and isopropanol precipitation. RNA 
(1.0 µg) was reverse transcribed to cDNA according to manufacturer’s 
instructions using the qScript cDNA SuperMix (Quanta Biosciences, #95048-
100). qPCR was performed using Light Cycler® FastStart DNA Master SYBR 
Green I (Roche, #12239264001) on a Light Cycler® 480 II Real-Time PCR 
System (Roche). qPCR cycling conditions with primer sequences (available upon 
request) and concentrations were performed as described previously.48  
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Immunoblotting 
 Western blots were performed as previously described.48 Western blots 
were probed using the following primary antibodies: PR-A/B (H-190) and p21 (C-
19) were purchased from Santa Cruz Biotechnology; FOXO1 (#2880) was 
purchased from Cell Signaling Technologies; and Actin (Sigma-Aldrich, #A4700). 
Phospho-Ser190 PR anti-sera was purchased from NeoMarkers (#MS-1331-P1). 
Custom made phospho-Ser294 PR antibodies (clone 8508) were commissioned 
from Thermo Fisher Scientific designed to recognize the following phospho-
specific peptide sequence: C-PMAPGR(pS)PLATTV-amide. HRP-conjugated 
goat anti-rabbit and goat anti-mouse (Bio-Rad, #170-6515 and #170-6516) 
secondary antibodies were used to detect their respective primary antibodies, 
and immunoreactive proteins were visualized on Kodak X-OMAT LS film 
(Carestream Health, #864-6770) following ECL detection with Super Signal® 
West Pico Maximum Sensitivity Substrate (Pierce, #34087). All Western blotting 
experiments were performed at a minimum in triplicate, and representative 
experiments are shown in each respective figure. 
Flow Cytometry 
 Cells were treated in 5% DCC with either 10 nM R5020 or equal volume 
vehicle (ethanol) for 96 hrs. Cells were collected, fixed and stained as described 
previously.48 Propidium iodide staining was detected using a LSRII (BD 
Biosciences, #H4760). Cells were gated for cell cycle phases using BD 
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Biosciences FACSDiva 8.0 software. Cell cycle profiles were analyzed using 
FlowJo vX software (Tree Star Inc.). 
Chromatin Immunoprecipitation (ChIP) 
 Cells were treated for 1 hr with either R5020 (10 nM) or equal volume 
vehicle (ethanol) in 5% DCC and cell samples were fixed, harvested, and lysed 
according to optimized manufacturer’s instructions using the ChIP-IT™ Express 
Magnetic Chromatin Immunoprecipitation Kit (Active Motif, #53008). Samples 
were homogenized using a Bioruptor sonicator (Diagenode, Inc.). ChIP reactions 
were incubated overnight on an end-to-end rotator using 100 µL of isolated 
chromatin and either 2 µg of PR-A/B antibody (Ab-8), FKHR (H-128) antibody 
(Santa Cruz Biotechnology, #sc-11350), or 0.4 µg of normal mouse or rabbit IgG 
(Santa Cruz Biotechnology, #sc-2025 # sc-2027). Samples were washed, eluted, 
reverse cross-linked, and treated with Proteinase K according to manufacturer’s 
instructions (Active Motif). DNA was analyzed by RT-qPCR as described above. 
5-bromo-2’-deoxyuridine (BrdU) Assay 
 Cells were plated in 96-well plates in IMEM plus 5% DCC. Twenty-four 
hours later, cells were treated with either R5020 (10 nM) or equal volume vehicle 
(ethanol) in IMEM plus 5% DCC for 96 hr. Three hours prior to the 96 hr 
timepoint, 10X BrdU from the BrdU Cell Proliferation Assay Kit (Cell Signaling, 
#6813) was prepared in IMEM and then added to each well for a final 
concentration of 1X. Plates were returned to a 37°C incubator with 5% CO2 for 3 
hr. Cells were fixed, DNA was denatured, and detection of BrdU incorporation 
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into cellular DNA during cell proliferation was conducted according to 
manufacturer’s protocol. 
Senescence Associated-β-galactosidase (SAβGal) Activity Assays 
 Cells were continuously treated for 96 hr in IMEM plus 5% DCC. Cells 
were washed, fixed, and stained for SAβGal activity according to manufacturer’s 
instructions using the Senescence β-Galactosidase Staining Kit (Cell Signaling 
Technology, #9860). Staining of cell nuclei was achieved with DAPI containing 
ProLong® Gold antifade reagent (Invitrogen, #P-36931). All bright-field and 
fluorescent cell images described herein were acquired with a Leica DM4000B 
microscope (Leica Microsystems, Inc.) and captured using the Leica Application 
Suite software (version 4.2). Percentage of positive SAβGal cells (blue staining 
with enlarged nuclei) was determined from quantifying three fields at 100X 
magnification using ImageJ software. Values were normalized to total nuclei 
present per field from DAPI staining. 
Statistical Analysis 
 All reported values represent the mean ± the standard deviation (SD). 
Data shown are representative of the indicated replicates of each experiment. 
Statistical analyses were performed using a Student’s t-test where significance 
was determined with 95% confidence (*p ≤ 0.05, **p ≤ 0.01). 
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3.3 RESULTS 
Creation of PR isoform specific ovarian cancer cell models. 
 Cell line models derived from human tumors frequently lose steroid 
receptors (SR) expression when propagated in monolayer tissue cultures. We 
detected low to negligible levels of PR mRNA and protein in a panel of well-
characterized ovarian cancer cell lines including the clear cell carcinoma cell line, 
ES-2.48 PR expression in these models was only modestly induced by estrogen. 
Thus, to study the impact of progesterone/PR signaling on ovarian cancer cell 
biology without the added complexity of estrogen addition (PR is an ER target 
gene), we generated ES-2 cell models stably expressing either PR-A or PR-B.  
We selected ES-2 cells due to their inherent aggressive nature and rapid growth 
rate159, low endogenous PR mRNA levels48, and molecular and genomic 
characteristics that are similar to primary tumors of high-grade serous ovarian 
carcinomas (the most common cancer of the ovary).160  
Pooled populations of PR-expressing cells as well as multiple clones of 
stable ES-2 cell lines expressing GFP-tagged PR-A, GFP-tagged PR-B (with the 
PR-A start site mutated), or GFP-only empty vector (EV) control were created 
(Figure 1A). GFP-tagged PRs are fully functional in COS and HeLa cell 
models.87, 161 To verify that GFP-tagged PR isoforms behave as ligand-activated 
transcription factors in progestin-treated ES-2 cells, PR transcriptional activity in 
pooled populations of ES-2 cells expressing EV control, PR-A, and PR-B was 
evaluated using PRE-luciferase reporter assays. Similar to results obtained in 
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breast cancer cell models79, PR-B was more transcriptionally active (~5-fold) 
relative to PR-A as measured using this minimal (2X-PRE-driven) promoter; the 
synthetic progestin R5020 (10 nM; for 18hr) significantly increased luciferase 
expression in cells expressing PR-A (1.8 fold) and PR-B (9.5 fold) relative to 
vehicle or EV (GFP-only) controls (Figure 1A). Both isoforms underwent a slight 
up-shift in gel mobility upon R5020 treatment (Figure 1A inset), indicating direct 
PR phosphorylation (further addressed below). Endogenous PR-A (HEF1)34 and 
PR-B (BIRC3)76, 162 target genes were also selectively upregulated in an isoform-
specific manner in pooled cell populations relative to vehicle and EV controls 
(Figure 1B).  
 Multiple clonal PR+ ES-2 cell lines were isolated and expanded after 
selection for PR protein expression levels comparable to PR expressed in T47D 
breast cancer cell lines stably expressing either PR-A only (YA), PR-B only (YB), 
or constitutively expressing both endogenous isoforms in the absence of 
estrogen (CO)86 (Figure 1C). One GFP-only EV control clone (EV #3), four GFP-
PR-A-expressing clones (PR-A #1, #5, #4, #7) and two GFP-PR-B-expressing 
clones (PR-B #1, #3) were selected for further study. PR phosphorylation status 
was examined in PR-containing clonal cell lines following R5020 (10 nM for 1 hr) 
treatment. Similar to pooled populations (Figure 1A inset), R5020 induced a 
subtle up-shift in PR gel mobility in studies with clonal cell lines as measured by 
Western blotting (Figure 1D). PR Ser190 is a constitutive phosphorylation site 
similarly present in each clone. PR Ser294 is a proline-directed (i.e. primarily  
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Figure 3-1: Stable expression of PR isoforms in ES-2 cells.  (A) Inset, Western blot 
analysis showing total PR expression in ES-2 cell pools expressing GFP-tagged empty 
vector control (EV), GFP-tagged PR-A (PR-A), or GFP-tagged PR-B (PR-B) and treated 
without or with R5020 (10 nM) for 24 hr. ES-2 cells expressing EV, PR-A, or PR-B were 
transiently transfected with a progesterone response element (2X-PRE) containing 
luciferase reporter gene and treated for 18 hr with R5020 (10 nM). Relative luciferase 
units (RLU) were normalized to the mean result ± standard deviation (SD) for Renilla 
luciferase expression (n=3, **p≤0.01). (B) RT-qPCR analysis of HEF1 and BIRC3 mRNA 
expression after 24 hr R5020 (10 nM) treatment in ES-2 cell pools expressing EV, PR-A 
or PR-B (n=3, *p≤0.05 **p≤0.01). (C) Western blot analysis of total PR expression in ES-
2 cells stably expressing GFP-tagged EV control  (clone #3), GFP-tagged PR-A (GFP-
PR-A clone #1, #5, #4, #7), or GFP-tagged PR-B (GFP-PR-B clone #1, #3) relative to 
T47D breast cancer cells stably expressing PR-A-only (YA), PR-B-only (YB), and both 
endogenous PR isoforms (CO). Actin served as a loading control. (D) Western blot 
analysis of PR-A and PR-B phosphorylation at Ser294 and Ser190, and total PR protein 
expression in ES-2 PR-expressing cells treated with R5020 (10 nM) for 1 hr. !! 
denotes a non-specific band present in the phospho-PR Ser294 blot. Actin served as a 
loading control.  
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phosphorylated by CDKs and/or MAPKs)163-165 phosphorylation site robustly 
phosphorylated in PR-B-expressing cells in the presence of R5020 (a non-
specific protein just below PR-B was detected in all lanes). Notably, PR-A-
expressing clones exhibited varied ligand-dependent phosphorylation of Ser294, 
with robust levels detected in PR-A-expressing clone #7 cells relative to clone #4 
cells. Phosphorylation of Ser294 occurs on PR-B, but not PR-A, in breast cancer 
cell models.79, 166 Together, these data confirm that GFP-tagged PR-A and PR-B 
stably expressed in ES-2 cells can bind ligand, undergo phosphorylation at well-
characterized sites, and selectively regulate isoform-specific endogenous target 
genes. 
PR isoforms regulate unique gene sets in ovarian relative to breast cancer 
cells.  
 To assign isoform-specific transcriptional actions to PR-A and PR-B stably 
expressed in ovarian cancer cells, we performed genome-wide transcriptional 
profiling of representative clonal ES-2 cell lines expressing either EV (clone #3), 
PR-A (clone #7), and PR-B (clone #1) following treatment without or with R5020 
(24 hr) and created representative heat maps (Figure 2A) and Venn diagrams 
(Figure 2B-C) illustrating isoform-specific gene regulation (>2-fold up or 
downregulated genes are shown). Cells expressing either PR-A-only or PR-B-
only regulate distinct gene clusters relative to the same parental cells expressing 
EV (GFP-only). Simply the expression of PRs in the absence of exogenously 
added ligand dramatically altered the transcriptome. Strikingly, in the absence of  
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Figure 3-2: Gene expression profiling of PR-A and PR-B transcriptional activity in 
ovarian and breast cancer cells.  (A) Heat map highlighting the transcriptional profiles 
between ES-2 ovarian cancer cells stably expressing EV control (clone #3), PR-A (clone 
#7), and PR-B (clone #1). Cells were treated with vehicle or R5020 (10 nM) for 24 hr and 
harvested RNA was subjected to Illumina gene profiling as described in Methods. Genes 
differentially expressed >2-fold are displayed for each treatment group. The experiment 
was performed in triplicate. (B) Venn diagrams showing the number of unique genes 
downregulated or upregulated >2-fold in the absence of R5020 treatment in PR-A- 
(clone #7) and PR-B-expressing (clone #1) cells. (C) Venn diagrams depicting the 
number of unique genes downregulated or upregulated >2-fold with R5020 treatment in 
PR-A- (clone #7) and PR-B-expressing (clone #1) cells. (D) Heat map highlighting the 
transcriptional profiles between breast cancer cells expressing EV control (T47D Y), PR-
A (T47D YA), and PR-B (T47D YB). The cells were treated with vehicle or R5020 (10 
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nM) for 24 hr and harvested RNA was subjected to Illumina gene profiling as in part A. 
Genes differentially expressed >2-fold are displayed for each treatment group. The 
experiment was performed in triplicate. (E) Venn diagrams depicting the number of 
unique genes downregulated or upregulated >2-fold in the absence of R5020 treatment 
in T47D YA and YB cells. (F) Venn diagrams depicting the number of unique genes 
downregulated or upregulated >2-fold with R5020 treatment in T47D YA and YB cells. 
 
ligand, PR-A altered the expression of more genes (100 genes downregulated 
and 61 genes upregulated) relative to PR-B (31 genes downregulated and 17 
genes upregulated; Figure 2B). In contrast, in the presence of ligand, PR-B (132 
genes upregulated and 69 genes downregulated) was the more active 
transcriptional regulator relative to PR-A (53 genes downregulated and 38 genes 
upregulated). These data suggest that PR-B is the dominant hormone-sensitive 
PR isoform in ovarian cancer cells, while PR-A may mediate significant ligand-
independent actions, but functions predominantly (in the absence or presence of 
ligand) via repressive actions (further addressed below). 
Regulation of isoform-specific PR target genes in ES-2 cells suggests 
important functional differences between PR isoforms (Figure 2B-C). To 
understand what specific cellular pathways may be isoform-specifically regulated, 
we performed Gene Ontology (GO) analysis for gene terms significantly 
regulated by either PR-A or PR-B (Figure 3). In the presence of progestin, gene 
terms significantly upregulated by PR-A (38 genes, 27 of which were also 
upregulated by PR-B) were enriched in cell adhesion, regulation of cell-substrate 
adhesion, extracellular matrix organization, and growth factor binding. Gene 
terms significantly downregulated by PR-B in response to progestin (69 genes,  
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Figure 3-3: Gene Ontology (GO) analysis of significantly regulated genes in PR-
expressing ovarian cancer cells.  Genes regulated >2-fold relative to vehicle treatment 
were analyzed for GO term enrichment as previously described.78 Analysis of the top 
ranked and significant GO terms are listed for PR-A and PR-B in a ligand-dependent and 
–independent manner. Significant terms have a Benjamini and Hochberg adjusted 
Fisher p-value of p≤0.05. 
 
  67 
30 of which were also down-regulated by PR-A) were also associated with 
regulation of the extracellular matrix, but significantly included genes associated 
with regulation of the basement membrane. Gene terms associated with 
pathways regulating the cellular response to oxygen levels were significantly 
upregulated by ligand-bound PR-B. Other PR-isoform specific regulated gene 
terms significantly associated with known pathways as defined by GO are listed 
in Figure 3.  
Differential regulation of PR isoform-specific target genes identified using 
the Illumina platform (Figure 2) was validated by RT-qPCR in multiple ES-2 
clones (Figure 4). Progestin-induced expression of selected PR-A and PR-B 
target genes was evaluated at 24 hr and 96 hr (R5020; 10 nM). PR-A target 
genes, CRISPLD1 and WISP1, known to be involved in the regulation of the 
extracellular matrix, were robustly induced following R5020 treatment of PR-A 
expressing clones (#4 and #7) relative to modest or insignificant regulation in PR-
B expressing clones (#1 and #3) (Figure 4A). CRISPLD1 belongs to a super-
family of proteins that have extracellular endocrine or paracrine functions and are 
also involved in the regulation of extracellular matrix and in cell-cell adhesion 
during fertilization.167 WISP1 binds to proteoglycans, decorin and biglycan, 
present in the extracellular matrix of connective tissues.168 PR-B target genes 
BIRC3 (a mediator of cancer cell pro-survival) and GZMA (a novel PR-B target 
gene identified herein and a mediator of cytotoxic T-cell responses significantly 
elevated in the serum of women with ovarian cancer169) were robustly induced  
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Figure 3-4: Validation of PR isoform-specific gene targets in ovarian cancer cells. 
RT-qPCR analysis of PR-A selective target gene mRNAs (A) encoding CRISPLD1 and 
WISP1 (A) or PR-B selective target gene mRNAs encoding BIRC3 and GZMA (B) 
following 24 hr and 96 hr R5020 (10 nM) treatment in ES-2 cells stably expressing EV 
control (clone #3), PR-A (clone #4,  #7), or PR-B (clone #1, #3) (n=3, *p≤0.05, **p≤0.01).  
 
in PR-B-expressing clones (#1 and #3) relative to weak or insignificant induction 
in PR-A-expressing clones (#4 and #7) or controls (Figure 4B).  
In contrast to its protective role in reproductive tissues, progesterone is a 
potent mitogen in the mammary gland.170 PR-B but not PR-A is required for 
ductal side-branching and alveologenesis that occurs during mammary gland 
development. Breast cancer cell models expressing PR-B, but not PR-A, grow in 
soft agar in response to progestin treatment.37, 76, 171 Indeed, both overlapping 
and isoform-specific PR target gene up- and downregulation have been 
extensively reported in breast cancer models.34, 35 To illustrate potentially distinct 
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transcriptional actions of PR isoforms in ovarian relative to breast cancer models, 
we repeated whole genome profiling studies in T47D cells stably expressing 
either PR-A-only (YA) or PR-B-only (YB), using the naturally occurring PR-null 
variant parental T47D cell line (Y) as a control. As above for ES-2 cells, T47D 
cells were treated with R5020 (10 nM) for 24 hr, and global gene expression 
profiles were measured using whole genome gene expression bead (Illumina) 
arrays. As in our ovarian cancer cell models, transcriptional differences between 
PR-null T47D cells and parental T47D cells stably expressing either PR-A or PR-
B were readily observed (Figure 2D). However, in sharp contrast to hormone-
naive ovarian cancer models, in the absence of progestin, breast cancer cells 
expressing PR-B upregulated more genes (194 genes) relative to cells 
expressing PR-A (111 genes) (Figure 2E). In the absence of ligand, expression 
of PR-A (168 genes) or PR-B (157 genes) resulted in downregulation of a similar 
number of genes from distinct but largely overlapping subsets (103 genes in 
common) (Figure 2E). In the presence of progestin, PR-A and PR-B both 
activated and repressed numerous genes from distinct but largely overlapping 
subsets. Thus, in contrast to PR expression in ovarian cancer models (where 
there is modest overlap between PR-A and PR-B regulated gene sets, and PR-B 
appears to be the dominant hormone-regulated isoform) PR expression in breast  
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Figure 3-5: Differential transcriptional regulation of PR isoform-specific target 
genes in ovarian and breast cancer cells.  (A) Venn diagrams depicting the number of 
unique genes upregulated or downregulated >2-fold in the absence of R5020 treatment 
in PR-A-expressing T47D YA and ES-2 PR-A #7 cells. (B) Venn diagrams depicting the 
number of unique genes upregulated or downregulated >2-fold with R5020 treatment in 
PR-A-expressing T47D YA and ES-2 PR-A #7 cells. (C) Venn diagrams depicting the 
number of unique genes upregulated or downregulated >2-fold in the absence of R5020 
treatment in PR-B-expressing T47D YB and ES-2 PR-B #1 cells. (D) Venn diagrams 
depicting the number of unique genes upregulated or downregulated >2-fold with R5020 
treatment in PR-B-expressing T47D YB and ES-2 PR-B #1 cells. The genes from the 
shared Venn category are listed.  
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cancer models exhibits moderate overlap between PR-A and PR-B regulated 
gene sets and both isoforms are highly responsive to hormone when these 
models are assayed using similar conditions (i.e. compare Figure 2 to Figure 5). 
We detected no differences in transcriptional activity between GFP-tagged PRs 
and untagged PRs in multiple cell types (data not shown). 
PR-B activates a FOXO1/p21 senescence program repressed by PR-A in 
ovarian cancer cells. 
 To more fully understand the basis of PR isoform-specific gene regulation 
in ovarian cancer cells, we considered the largely repressive actions of (primarily 
unliganded) PR-A relative to the predominantly hormone-sensing actions of 
(liganded) PR-B (compare Figure 6A, left to right Venn diagram). Only four genes 
were significantly repressed by PR-A and activated by liganded-PR-B: KYNU, 
FOXO1, p21, and ZDHHC9 (Figure 6A). KYNU is involved in the biosynthesis of 
NAD cofactors from tryptophan catabolism through the kynurenine pathway. The 
expression of KYNU is significantly downregulated in several cancer types, such 
as in invasive ductal breast carcinomas172, pediatric acute myeloid leukemias 
harboring IDH mutations173, and highly aggressive osteocarcinoma cell lines.174 
ZDHHC9 is a palmitoyltransferase specific to HRAS and NRAS175 and reported 
to be widely overexpressed in human cancers.176 Notably, we previously 
identified both FOXO1 and p21 as required factors for progestin-mediated 
cellular senescence in PR-B+ ovarian cancer cells.48 Our microarray experiments 
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Figure 3-6: Progestin treatment induces isoform-specific differential expression of 
cellular senescence mediators in ovarian cancer cells.  (A) Venn diagram describing 
the number of unique genes downregulated in the absence of R5020 treatment in ES-2 
cells stably expressing PR-A (clone #7) and upregulated in ES-2 cells stably expressing 
PR-B (clone #1) with R5020 treatment. Four genes from the shared Venn category are 
listed. (B) Relative gene expression of FOXO1 and p21 in ES-2 cells stably expressing 
EV control (clone #3), PR-A (clone #7), or PR-B (clone #1) treated with vehicle or R5020 
(10 nM) for 24 hr as determined by Illumina microarray experiments (Figure 2A). RT-
qPCR analysis of (C) FOXO1, (D) p21, and (E) p15 mRNA expression following 24 hr 
and 96 hr R5020 (10 nM) treatment of ES-2 cells stably expressing EV control (clone 
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#3), PR-A (clone #4, #7), PR-B (clone #1, #3) (n=3, *p≤0.05, **p≤0.01). (F) Western blot 
analysis of PR, FOXO1, and p21 protein expression in ES-2 cells stably expressing PR-
A (clone #4, #7) or PR-B (clone #1, #3) after 96 hr treatment of R5020 (10 nM). Actin 
served as a loading control. (G) ChIP assays showing PR recruitment to a PRE-
containing region of the p21 promoter. EV control and PR-A-expressing cells (clone #4, 
#7) were stimulated with vehicle or R5020 (10 nM) for 1 hr. Fixed lysates were subjected 
to ChIP assays as described in Methods using specific antibodies targeting PR (or IgG 
control). (H) ChIP assays demonstrating detection of H3K4me2 at the PRE-containing 
region of the p21 promoter. EV control, PR-A- (clone #7), and PR-B-expressing (clone 
#1) cells were stimulated with vehicle or R5020 (10 nM) for 1 hr. Fixed lysates were 
subjected to ChIP assays as described in Methods using specific antibodies targeting 
H3K4me2 (or IgG control).  
 
revealed repression of both p21 and FOXO1 mRNA expression in untreated or  
treated PR-A-expressing (clone #7) ES-2 cells relative to EV (clone #3) controls 
(Figure 6B). In contrast to PR-A+ cells, R5020 treatment (24 hr) significantly 
upregulated p21 and FOXO1 mRNA in PR-B+ cells (clone #1). These results (i.e. 
robust PR-B-selective upregulation of FOXO1, p21, and the FOXO1 target gene, 
p15) essentially repeated by RT-qPCR in multiple clones of ES-2 cells stably 
expressing either PR-B-only or PR-A-only and treated with R5020 for 24-96 hrs 
(Figure 6C-E). FOXO1, p21, and p15 mRNA levels were either slightly 
upregulated or unchanged in PR-A+ cells relative to their pronounced induction in 
PR-B+ cells (24 hr). These genes were also insensitive to progestin in EV+ 
(clone #3) controls (Figure 6C-E). Western blot analysis confirmed these results 
(Figure 6F), demonstrating robust upregulation of FOXO1 and p21 protein within 
96 hr R5020 treatment in PR-B+ clones (#1 and #3) but not in PR-A+ clones (#4 
and #7). Taken together, these data indicate that while progestin-treated PR-A+ 
cells are capable of modestly inducing FOXO1 and p21 at the mRNA level, 
changes in protein expression do not persistently manifest (i.e. by as late as 96 
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hrs). In the presence of progestin, PR-B is a stronger transcriptional activator of 
known senescence mediators relative to PR-A.  
 To demonstrate the repressive action of PR-A on the p21 promoter, we 
performed chromatin immunoprecipitation (ChIP) assays to determine if liganded 
PR-A binds to PRE-containing regions of the endogenous p21 promoter. Indeed, 
in the presence of progestin, PR-A was significantly recruited (9- and 21-fold in 
clones #3 and #7, respectively) to a PRE-containing region downstream of the 
p21 transcriptional start site previously identified by ChIP-Seq studies conducted 
in PR+ breast cancer models102 and validated in our previous study48; PR 
recruitment to this region in EV control (clone #3) cells was minimal and similar to 
background (IgG control) levels (Figure 6G). We previously reported48 similar 
recruitment (5-fold relative to controls) of PR-B to the same PRE-containing 
region following R5020 treatment (data not shown). 
 Taken together, our data suggest that PR-B-containing transcriptional 
complexes activate p21 transcription, while PR-A-containing complexes are 
repressive. Changes in gene expression are linked to epigenetic histone tail 
modifications, such as methylation and acetylation. Histone H3 Lys4 
dimethylation (H3K4me2) is an epigenetic modification associated with 
transcriptional activation. To measure the level of H3K4me2 (i.e. as a surrogate 
marker of p21 gene activation) at the same PRE/PR-containing p21 promoter 
region, EV control (clone #3), PR-A-expressing (clone #7), and PR-B-expressing 
(clone #1) cells were treated with vehicle control or R5020 (10 nM for 1 hr) and 
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the degree of histone H3 Lys4 dimethylation was measured by ChIP assay 
(Figure 6G). H3K4me2 levels were significantly elevated (6-fold) only in 
progestin-treated ES-2 cells stably expressing PR-B (clone #1) relative to ES-2 
cells stably expressing PR-A (clone #7) and EV (clone #3) vehicle controls. 
These results suggest that PR-A is recruited to the p21 promoter but is incapable 
of mediating robust hormone-dependent p21 gene activation. 
PR-B robustly induces cellular senescence relative to PR-A in ovarian 
cancr cells. 
 To account for the differences in PR isoform-specific regulation of 
senescence mediators (Figure 6), we evaluated the senescence phenotype in 
PR-A and PR-B expressing ES-2 cells. Our previous study demonstrated that in 
the presence of progestin, PR-B promoted cellular senescence, a cell fate 
wherein cells remain viable and long-lived, but are non-proliferative.48 A common 
marker of cellular senescence is the accumulation of endogenous lysosomal β-
galactosidase. We estimated the percentage of senescent ES-2 cells via 
measurement of the activity of senescence-associated β-galactosidase (SAβGal) 
at pH 690 (i.e. blue stained cells with enlarged nuclei). Representative images 
showing SAβGal and DAPI staining performed in clonal ES-2 cell lines 
expressing EV (clone #3), PR-A-only (clone #7), or PR-B-only (clone #1) and 
treated (96 hr) with either R5020 or vehicle control are depicted (Figure 7A) 
along with quantitation of SAβGal positive cells in five clonal cell lines (Figure 
7B). As expected, R5020 (96 hr) significantly induced senescence as measured  
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Figure 3-7: PR isoform expression and activity induces cellular senescence. 
(A) Representative staining for SAβGal activity in EV control (clone #3), PR-A- (clone #7) 
or PR-B-expressing (clone #1) ES-2 cells treated with R5020 (10 nM) for 96 hrs 
(magnification = 100X). Cell samples were mounted onto glass slides using ProLong® 
Gold Antifade Reagent with DAPI (Invitrogen) for bright-field and fluorescent microscopy. 
B) Percentage of positive SAβGal cells in EV control (clone #3) and PR-A- (clone #4, #7) 
and PR-B-expressing (clone #1, #3) cells treated with R5020 (10 nM) for 96 hr was 
determined by quantifying three fields at 100X magnification. Values were normalized to 
total nuclei present in each field as determined by DAPI staining (n=3, **p≤0.01). (C) 
BrdU incorporation analysis of EV control (clone #3), PR-A- (clone #4, #7) or PR-B-
expressing (clone #1, #3) cells continuously treated with R5020 (10 nM) for 96 hrs. BrdU 
was added to the wells, and cells were incubated for 3 hr prior to fixing the cells and 
denaturing the DNA according to manufacturer’s protocol (n=2, **p≤0.01). (D) Cell cycle 
analysis by propidium iodide staining of EV control (clone #3) PR-A- (clone #4, #7) or 
PR-B-expressing (clone #1, #3) cells treated with R5020 (10 nM) for 96 hr (n=2, *p≤0.05 
**p≤0.01).  
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by SAβGal in PR-B-expressing ES-2 cells (clones #1 and #3 exhibited 51% and 
59% positive cells, respectively) relative to vehicle controls. In contrast, PR-A-
expressing ES-2 cells (clones #4 and #7) exhibited significantly less SAβGal 
(21% and 22%, respectively) relative to PR-B-expressing ES-2 cells. Minimal 
SAβGal levels were observed in EV #3 (2%) and vehicle-treated cells (Figure 7A-
B).  
 Cellular senescence is often associated with a decrease in cell 
proliferation that is accompanied with cell cycle exit (i.e. cells accumulate in G1). 
Thus, we examined BrdU incorporation to detect altered proliferation following 
progestin treatment of PR-expressing ovarian cancer cells. After 96 hr R5020 
treatment, BrdU incorporation was significantly inhibited in PR-B-expressing cell 
clones, indicating that R5020 attenuated DNA synthesis and halted proliferation. 
R5020 treatment did not significantly alter BrdU incorporation in EV (clone #3) 
and PR-A-expressing (clone #4) cells, and only weakly inhibited PR-A+ clone #7 
cells relative to that observed in PR-B-expressing clones (Figure 7C). Finally, cell 
cycle (FACS) analysis of PR-B-expressing cells, as measured by propidium 
iodide staining, confirmed a significant increase in the percentage of cells in the 
G0/G1
 
phase of the cell cycle accompanied by a decrease in the percentage of 
cells in S phase following 96 hr of R5020 exposure relative to vehicle controls 
(Figure 7D). Similar to the above findings using BrdU, progestin treatment elicited 
minimal or insignificant effects on the cell cycle distribution of ES-2 cells 
expressing either EV (clone #3) or PR-A (clones #4 and #7; weak but significant 
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effects were again observed in PR-A clone #7). Taken together, our data suggest 
that in the presence of progestin, PR-B is a stronger promoter of cellular 
senescence relative to PR-A in ovarian cancer cells.  
Active FOXO1 expression confers PR-B-like behavior to PR-A-containing 
cells.  
Similar to cell cycle studies performed in breast cancer models,37, 124 
relative to PR-B, PR-A often fails to elicit robust induction of cell cycle mediators 
(p21) and their associated biological responses (i.e. biphasic regulation of cell 
proliferation in breast models), but may weakly mimic PR-B. Progestin treatment 
weakly induced FOXO1 mRNA expression (Figure 6C) but did not modulate 
protein levels (Figure 6F) in FOXO1-expressing PR-A+ clones (#4 and #7) 
relative to PR-B+ clones (at 96 hr). We thus evaluated if FOXO1 activity was 
required for the weak but significant induction of cellular senescence in PR-A-
expressing clone #7 using the selective FOXO1 small molecule inhibitor, 
AS1842856 (AS)48, 103 (Figure 8). R5020 treatment of PR-A+ (clone #7) ES-2 
cells for 96 hr modestly induced FOXO1 protein and mRNA expression relative to 
vehicle controls (Figure 8A-B). Treatment with AS alone did not affect basal PR-
A or FOXO1 protein and mRNA expression, but AS blocked R5020-induced 
FOXO1 protein and mRNA expression (Figure 8A-B). FOXO1 gene expression is 
known to be auto-regulated (i.e. FOXO1 contributes to regulation of its own gene 
expression).177 Similar results were observed for R5020-induced p21 and p15  
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Figure 3-8: PR-A-induced cellular senescence is dependent on FOXO1 activity.   
(A) Western blot analysis of PR and FOXO1 protein expression in PR-A-expressing 
(clone #7) cells treated with vehicle control, R5020 (10 nM), AS1842856 (AS, 100 nM), 
or the combination of AS1842856 and R5020 for 96 hrs. Densitometry of FOXO1 protein 
expression in each treatment group is included in the figure. RT-qPCR analysis of (B) 
FOXO1, (C) p15, and (D) p21 mRNA expression in PR-A-expressing (clone #7) cells 
treated with R5020 (10 nM), AS1842856 (AS, 100 nM), or the combination of 
AS1842856 and R5020 for 96 hrs. (E) Representative staining for SAβGal activity of PR-
A-expressing (clone #7) cells treated with R5020 (10 nM), AS1842856 (AS, 100 nM), or 
the combination of AS1842856 and R5020 for 96 hrs (magnification = 100X). Cell 
samples were mounted onto glass slides using ProLong® Gold Antifade Reagent with 
DAPI (Invitrogen) for bright-field and fluorescent microscopy. Percentage of positive 
SAβGal cells was determined from quantifying three fields at 100X magnification. Values 
were normalized to total nuclei present in each field from DAPI staining (n=3, **p≤0.01).  
 
mRNA expression (Figure 8C-D). Consistent with these results, progestin-
induced senescence, as measured by SAβGal activity, was significantly reduced 
upon inhibition of FOXO1 by AS (100 nM) in combination with R5020 for 96 hr 
relative to R5020-only treated controls (Figure 8E). Together, these data 
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implicate FOXO1 as a required mediator of senescence-associated gene 
expression in PR-A+ ES-2 cells treated with progestin. 
 We speculated that overexpression of FOXO1 in PR-A-expressing cells 
would confer PR-B-like behavior and thereby “rescue” hormone sensitivity and 
senescence-associated gene regulation similar to that induced in PR-B+ cells. 
PR-A-expressing ES-2 clones were screened for low to undetectable FOXO1 
protein levels by Western blot (Figure 9A). These clones were fully capable of 
inducing robust expression of the PR-A target gene WISP1, but failed to 
upregulate PR-B-selective genes including FOXO1 following 96 hrs R5020 
treatment (data not shown). The PI3K/AKT pathway is activated in a majority of 
ovarian cancers178 and inactivates forkhead family transcription factors. 
Phosphorylation of FOXO1 at Thr24, Ser256, and Ser319 negatively regulates its 
nuclear localization and transcriptional activity152, 179; we therefore utilized the 
constitutively active form of FOXO1 (FOXO1-AAA) that cannot be 
phosphorylated by AKT.148 FOXO1-AAA or empty vector control (EV) were stably 
expressed by retroviral transduction of PR-A+/FOXO1-low (clones #1 and #5) 
ES-2 cells. Expression of total FOXO1 protein was confirmed by Western blotting 
(Figure 9A). Notably, R5020 only weakly increased p21 mRNA expression after 
96 hr in PR-A+ (clone #1) cells expressing EV (FOXO1-null) control. However, 
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Figure 3-9: Active FOXO1 restores PR-A sensitivity to progestins and induces 
cellular senescence.  (A) Western blot analysis of PR and FOXO1 protein expression 
in PR-A-expressing cells (clone #1, #5) stably expressing either EV control or 
constitutively active FOXO1 (AAA). Actin served as a loading control. (B) RT-qPCR 
analysis of p21 mRNA expression in cells expressing PR-A (clone #1, #5) and either EV 
control or constitutively active FOXO1 (AAA) and treated with vehicle or R5020 (10 nM) 
for 24 hr and 96 hr (n=3, *p≤0.05 **p≤0.01). (C) ChIP assays showing PR and FOXO1 
recruitment to the p21 promoter. PR-A-expressing (clone #1) cells stably expressing 
either EV control or constitutively active FOXO1 (AAA) were stimulated with vehicle or 
R5020 (10 nM) for 1 hr. Fixed lysates were subjected to ChIP assays as described in 
Methods using antibodies targeting PR, FOXO1, or IgG control and RT-qPCR was 
performed on isolated DNA. (D) Representative staining for SAβGal activity in PR-A-
expressing cells (clone #1) expressing either EV control or constitutively active FOXO1 
(AAA) and treated with vehicle or R5020 (10 nM) for 96 hrs (magnification = 100X). Cell 
samples were mounted onto glass slides using ProLong® Gold Antifade Reagent with 
DAPI (Invitrogen) for bright-field and fluorescent microscopy. Percentage of positive 
SAβGal cells in PR-A-expressing cells (clone #1, #5) expressing either EV control or 
constitutively active FOXO1 (AAA) and treated with vehicle or R5020 (10 nM, 96 hr) was 
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determined from quantifying three fields at 100X magnification. Values were normalized 
to total nuclei present in each field from DAPI staining (n=2, **p≤0.01). (E) Western blot 
analysis of PR phosphorylated on Ser294 or Ser190 and total PR in PR-A+ (clone #1) 
cells stably expressing either EV control or constitutively active FOXO1 (AAA) treated 
with either vehicle control, R5020 (R50, 10 nM) or CDB-4124 (CDB, 1 µM) for 1 hr. (F) 
RT-qPCR analysis of GZMA and IGFBP1 mRNA expression in PR-A-expressing cells 
(clone #1, #5) co-expressing either EV control or constitutively active FOXO1 (AAA) and 
treated with vehicle or R5020 (10 nM) for 24 hr and 96 hr (n=3, *p≤0.05 **p≤0.01).  
 
forced FOXO1-AAA expression in these cells significantly further increased p21 
mRNA induction in the presence of R5020 relative to vehicle controls at both 24 
hr and 96 hr (Figure 9B). These results essentially repeated in an additional ES-2 
cell line co-expressing PR-A (clone #5) and FOXO1-AAA (Figure 9B). Similar 
results were observed in HeLa cells transiently expressing PR-A and FOXO1 as 
measured via 2X-PRE-luciferase reporter assays and RT-qPCR analysis of p21 
expression (Figure 10).  
 
Figure 3-10: FOXO1 enhances progestin-dependent PR-A transcriptional activity 
in Hela cells.  (A) HeLa cells were transiently cotransfected with GFP-tagged PR-A, 
either the pcDNA3.1 empty vector (pc-EV) control or FOXO1 WT (pc-FOXO1 WT) 
vector, and a progesterone response element (2XPRE) containing luciferase reporter 
gene construct. Cells were treated for 18 hr with R5020 (10 nM). Relative luciferase 
units (RLU) were normalized to the mean result ± standard deviation (SD) for Renilla 
luciferase expression (n=3, **p≤0.01). (B) RT-qPCR analysis of p21 mRNA expression 
after 24 hr R5020 (10 nM) treatment in HeLa cells transiently cotransfected with GFP-
tagged PR-A and either the pcDNA3.1 empty vector (pc-EV) control or FOXO1 WT (pc-
FOXO1 WT) vector (n=3).  
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 ChIP assays revealed that upon R5020 treatment (10 nM; 1 hr), PR-A was 
again recruited to the p21 promoter in PR-A+ EV-expressing (clone #1) cells, and 
significantly further recruited upon exogenous FOXO1-AAA expression (Figure 
9C). FOXO1-AAA recruitment to this site also occurred in the absence of ligand 
but was significantly increased in response to R5020 treatment (Figure 9C). 
Consistent with these results, overexpression of FOXO1-AAA in PR-A+ cells 
(clones #1 and #5) conferred increased SAβGal activity upon R5020 treatment 
relative to vehicle and EV controls (Figure 9D). The level of SAβGal activity 
detected in FOXO1-AAA overexpressed PR-A+ ES-2 cells was similar to that of 
PR-B+ cells when treated with R5020 (Figure 5A-B). Induction of SAβGal in 
R5020-treated PR-A+ cells expressing FOXO1-AAA (but not EV) was 
accompanied by cellular senescence-associated changes in cell cycle 
distribution (i.e increased percentage of cells in G0/G1; data not shown).  
 These data suggest that expression of activated FOXO1-AAA in PR-A+ 
cells confers PR-B-like behavior (i.e. hormone responsive induction of p21 and 
senescence). To understand the mechanism for this effect, we assayed ligand-
dependent and independent PR phosphorylation as a surrogate marker of 
heightened progesterone responsiveness.180 Notably, phosphorylation of PR-B 
Ser294 mediates changes in PR-B promoter selection and hormone sensitivity, 
primarily assayed in breast cancer models.38, 78, 79, 181 We included both R5020 (a 
PR agonist) and the selective PR antagonist, CDB-4124 (CDB). Surprisingly, 
while PR-Ser190 phosphorylation remained unaltered across all conditions, 
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addition of either R5020 or CDB similarly induced robust PR-Ser294 
phosphorylation in PR-A+ (clone #1) ES-2 cells expressing FOXO1-AAA relative 
to EV-expressing and vehicle-treated controls (Figure 9E). Similar results were 
observed in a separate PR-A+ ES-2 clone (#5; data not shown). These data 
suggest that overexpression of activated FOXO1-AAA enhances PR-A Ser294 
phosphorylation and transcriptional activity in a manner similar to PR-B activity 
on PR-B-selective target genes (e.g. p21). Surprisingly, overexpression of 
FOXO1-AAA in PR-A+ (clones #1 and #5) cells also significantly increased 
mRNA expression of the PR-B-selective genes, GZMA and IGFBP1 (Figure 9F). 
Together, these data suggest that FOXO1 is a key mediator of enhanced 
hormone sensitivity on selected PR target genes (p21, GZMA, IGFBP1). Ligand-
bound PR-A is fully capable of undergoing phosphorylation at Ser294 and 
regulating PR-B-only target genes when activated FOXO1 is present.  
 PR-A is capable of inhibiting the transcriptional activity of PR-B, as well as 
other SRs, including glucocorticoid, mineralocorticoid, androgen, and estrogen 
receptors.106 Trans-repression of PR-B by PR-A has been primarily measured 
using reporter-gene assays182, 183 rather then on endogenous genes and requires 
PR-A SUMOylation.184 Our data suggest that PR-A is primarily repressive on the 
p21 promoter, but high levels of activated FOXO1 reversed this effect and 
enhanced both PR-A Ser294 phosphorylation and hormone sensitivity (i.e. of PR-
A on PR-B target genes). To address PR-B target gene expression when PR-A 
and PR-B are co-expressed, we transiently transfected PR-A into PR-B- 
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Figure 3-11: PR-A transactivates PR-B in PR-B-expressing ovarian cancer cells. 
(A) GFP-tagged empty vector (N3-EV) or GFP-tagged PR-A (4 µg) were transiently 
transfected into PR-B-expressing (clone #1) ES-2 cells with a p21 promoter-driven 
luciferase reporter construct and treated for 24 hr with R5020 (10 nM). Relative 
luciferase units (RLU) were normalized to the mean result ± standard deviation (SD) for 
Renilla luciferase expression (n=2, *p≤0.05, **p≤0.01, !!p≤0.01). RT-qPCR analysis of 
(B) p21, (C) GZMA, and IGFBP1 mRNA expression in PR-B-expressing (clone #1) cells 
transiently transfected with either GFP-tagged empty vector (N3-EV) or GFP-tagged PR-
A (0.5 µg). Cells were treated for 24 hr with R5020 (10 nM) (n=2, **p≤0.01, !!p≤0.01).    
 
expressing ES-2 cells. PR-B+ ES-2 cells (clone #1) were transiently transfected 
with either GFP-tagged EV (control) or GFP-tagged PR-A and a p21-promoter-
driven luciferase reporter48 (Figure 11A). As previously reported48 R5020 (10 nM 
for 24 hr) significantly induced p21 promoter activity in PR-B-only expressing 
cells containing the EV control (~2-fold) as measured using p21-luciferase 
assays. Surprisingly, transient expression of PR-A further increased ligand-
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induced p21 promoter activity (5-fold) in PR-B+ ES-2 cells. These results were 
confirmed at the level of transcription of the endogenous p21 promoter; addition 
of PR-A to PR-B+ ES-2 cells (clone #1) significantly increased p21 mRNA 
expression (i.e. from 3-fold in EV-expressing cells to 6-fold upon addition of PR-
A; Figure 11B). Furthermore, in the presence of progestin, the PR-B-selective 
genes, GZMA and IGFBP1, were significantly increased upon expression of PR-
A in PR-B+ ES-2 cells (clone #1; Figure 11C). Overall, our data suggest that 
when FOXO1 is present (a PR-B target gene), PR-A is equally hormone 
responsive (i.e. relative to PR-B) and capable of robust transactivation of 
selected PR-B target genes (p21, GZMA, IGFBP1). 
Progestins upregulate p21 and FOXO1 mRNAs in PR-B positive ovarian 
tumors 
 To validate our novel in vitro findings in ovarian cancer cell line models 
defined herein, we assessed the impact of PR signaling in primary human 
ovarian tumors using an innovative ex vivo culture system.149-151 Notably, tumor 
tissues cultured using this 3D system retain features of the original tumor, 
including SR expression. As illustrated in Figure 12A, ex vivo cultures of fresh 
primary ovarian tissue obtained from cytoreductive surgery were established 
using dissected tissues mounted on pre-soaked gelatin sponges equilibrated in 
culture media containing either vehicle control or R5020 (10 nM, 48 hr). A total of 
seven de-identified ovarian carcinoma tissues were obtained from the University 
of Minnesota’s tissue procurement facility (BioNet) and cultured as described in  
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Figure 3-12: Progestin mediates p21 and FOXO1 expression ex vivo in PR+ human 
primary ovarian tumors.  (A) Workflow schematic of ex vivo ovarian tumor explant 
assay as described in Methods. (B) Overview of patient age, final diagnosis, PR 
expression, and significant regulation of FOXO1 or p21 mRNA levels with R5020 (10 
nM) treatment in seven ovarian cancer tumors collected in this study. ✔ denotes positive 
expression of PR-A or PR-B as determined by Western blot analysis (as in C-D). ", #, 
or NS denote significant upregulation, downregulation, or no significance, respectively, 
of R5020-induced changes in the expression of p21 and FOXO1 mRNA levels relative to 
same-tumor vehicle controls. (C-D) PR protein (Western blots; left) and p21 and FOXO1 
mRNA (RT-qPCR; right) expression in human ovarian patient tumor OVC-1 and OVC-6 
explants treated without (vehicle) or with R5020 (10 nM) for 48 hrs. In Western blots, PR 
isoforms expressed in explants are shown relative to T47D CO breast cancer cells 
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(positive control); actin served as a loading control. Data reflect the mean of duplicate 
samples. (E) Proposed model of PR-A- and PR-B-induced cellular senescence in 
ovarian cancer cells. PR-A primarily acts to repress expression of p15 or p21 and weakly 
induce cellular senescence in PR-A+ cells. In contrast, hormone-stimulated PR-B+ cells 
upregulate FOXO1, p21, and p15 expression. Elevated levels of FOXO1 (a PR-B target 
gene) then cooperate with PR-B to further upregulate FOXO1, p15, and p21 expression 
and robustly induce cellular senescence. Expression of PR-A in PR-B+/FOXO1+ 
significantly enhances progestin-dependent expression of PR-B target genes, p21, 
GZMA, and IGFBP1 and promotes cellular senescence. In the absence of FOXO1 
expression, PR-A and PR-B regulate proliferative and/or pro-survival genes to promote 
alternate genetic programs.  
 
Methods (Figure 12B). Tumors included in this study expressed the PR-B isoform 
only or both PR-A and PR-B (Figure 12B); we did not observe any tumors 
expressing PR-A only. A high-grade serous subtype tumor (OVC-1) retained 
expression of the PR-B isoform (two film exposures depicting PR isoform 
expression in tumor lysates and T47D CO whole cell lysate as a positive control 
are shown; Figure 12C). In the presence of progestin, FOXO1 and p21 mRNA 
expression were significantly induced relative to vehicle controls (Figure 12C). A 
separate PR-B+ primary ovarian tumor (OVC-6) was similarly responsive to 
progestin treatment (48 hr); p21 mRNA but not FOXO1 mRNA expression was 
significantly induced upon R5020 treatment (Figure 12D). Additional hormone-
responsive tumors are indicated (Figure 12B). These data confirm that 
endogenously expressed PR-B induces p21 and FOXO1 expression in 
unmodified human primary tumors exposed to progestin. However, significant 
tumor heterogeneity in the response of ovarian tumors to progestins may relate 
in part to PR isoform expression as well as FOXO1 expression and activity (i.e. 
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as influenced by kinases that inactivate FOXO1 via phosphorylation events; see 
discussion). 
 Herein, our findings are consistent with a model that underscores the 
importance of activated (i.e. de-phosphorylated) FOXO1 as a mediator of PR 
hormone responsiveness (Figure 12E). In the absence of FOXO1 expression, 
PR-A primarily represses cellular senescence mediators, p21 and p15, and 
remains relatively insensitive to added progestin. In sharp contrast, PR-B-
expressing cells induce abundant FOXO1, p21, and p15 expression in response 
to hormone. FOXO1 and PR-B further cooperate to promote a robust cellular 
senescent phenotype.48 When both isoforms are present, active FOXO1 confers 
increased hormone responsiveness to PR-A at PR-B target genes, effectively 
“switching” the genetic programming to induce robust cellular senescence. 
Overall, we conclude that limiting expression of FOXO1 or AKT-driven FOXO1 
phosphorylation and inactivation are important inputs to predicting 
progesterone/PR-driven responses in ovarian cancers. 
 
3.4 DISCUSSION 
PR isoform expression in ovarian tumors. 
 Herein we modeled PR isoform expression in ovarian cancer cells to 
understand mechanisms of progesterone/PR-driven gene expression and cell 
biology. To date, two studies with large patient cohorts have examined the 
relative distribution of total PR levels within ovarian carcinomas. We first reported 
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that in a cohort of 504 ovarian tumors, 35% were PR+, with the highest PR 
expression in endometrioid (67%) and serous (35%; low grade serous, 64%) 
subtypes.48 In accordance with our study, the international Ovarian Tumor Tissue 
Analysis (OTTA) consortium examined the association of ER and PR expression 
and survival in 2,933 invasive epithelial ovarian tumors with similar results.49 
Furthermore, the OTTA study confirmed the prognostic significance of PR 
expression in ovarian tumors; high PR expression (≥50% tumor cell nuclei 
staining) in high-grade serous ovarian carcinomas was associated with a 
significant improvement in survival.  
PR isoforms are expressed from a single gene via alternate usage of at 
least two internal translational start sites (thus potentially creating full-length PR-
B, truncated PR-A, or further truncated and transcriptionally inactive PR-C 
isoforms). Although numerous mRNAs capable of encoding both PR-A and PR-B 
have been characterized185, isoform-specific expression is also regulated via two 
distinct upstream (i.e. distal and proximal) promoter regions.186 At least three 
studies8-10 have reported differential expression of PR isoforms in ovarian 
tumors. Akahira and colleagues8 investigated PR-A and PR-B by 
immunohistochemistry of 107 patient tumors. They observed the dominant 
expression of PR-B across all of the histological subtypes, with PR-B frequently 
expressed in the serous subtype; PR-A was weakly expressed in mucinous 
followed by serous.8 In a follow-up study, Akahira et al evaluated PR isoform 
expression via immunohistochemical staining in normal (n=8), benign serous 
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cystadenomas (n=10), borderline serous adenocarcinomas with low malignant 
potential (n=8), and malignant serous adenocarcinomas (n=24).9 They reported 
that PR-A expression was decreased or absent in malignant tissues relative to 
normal, whereas PR-B expression was present across all tissue cases in that 
study. The authors concluded that the absence of PR-A expression in malignant 
ovarian tissues is associated with the development of ovarian tumors. Finally, 
Lenhard et al10 examined the expression of PR isoforms in 155 ovarian patient 
cases, and reported PR-B expression in serous and endometrioid subtypes, 
while PR-A was present in serous followed by modest expression in 
endometrioid and clear cell.10 Ultimately, these studies observed dominant 
expression of PR-B in ovarian tumors across all subtypes with reduced or absent 
expression of PR-A. The mechanism for loss of PR-A relative to PR-B in 
malignant ovarian tumors is unknown. However, in endometrial cancer cells, 
enhanced DNA methylation was detected at the PR gene locus when PTEN 
expression was deleted.187 Approximately 7% of ovarian tumors evaluated in the 
2011 TCGA analysis41 harbored PTEN deletions, while 18% and 9% contained 
activating mutations of either PI3K or AKT, respectively.41 Similar to these 
findings in ovarian cancer, methylation of the PR-A but not PR-B promoter 
upstream of the PR gene occurs in advanced breast cancers and is significantly 
associated with tamoxifen-resistance.188  
To our knowledge, we are the first to examine the biological 
consequences of PR isoform-specific gene regulation in ovarian cancer models, 
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as well as to directly compare PR isoform-selective transcriptomes between 
ovarian and breast cancer models cultured under similar conditions (Figures 2, 5, 
and 6). Remarkably, in ovarian cancer models, we found that PR-A 
predominantly up- or down-regulates genes independently of ligand, while PR-B 
is the dominant hormone-responsive receptor; we were also surprised to 
discover relatively modest overlap between PR-A and PR-B target genes. In 
contrast, we observed much target gene overlap between PR-A and PR-B in 
similarly designed breast cancer models, where relative to PR-A, PR-B 
predominantly up-regulated target genes in the absence of progestin. Ligand-
independent actions of PR-B have been well-characterized in breast cancer 
models78, 171, 189 Surprisingly, there was also relatively little overlap between 
ovarian and breast cancer models with regard to hormone-regulated PR-target 
genes, with nine genes regulated by PR-A and 16 genes regulated by PR-B in 
both breast and ovarian cancer models (Figure 5). However, while PR-A- and 
PR-B-regulated genes were distinct in ovarian relative to breast cancer models, 
both isoforms regulated similar pathways involved in cell growth, proliferation, 
cell death, and survival (as predicted using Ingenuity Pathway analysis).  
Progesterone is proliferative in breast, but inhibitory in reproductive 
tissues. 
 The paradoxical effects of progesterone observed in ovarian relative to 
breast cancer models may be attributed to differential co-factor availability190 
(discussed below) as well as differential cross-talk between PR and growth 
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factor-mediated signaling pathways (i.e. protein kinases). PR-B, but not PR-A, 
functions outside the nucleus to rapidly activate protein kinases (c-Src, MAPK, 
AKT) in part via ligand-induced interaction between a poly-Pro-rich region unique 
to PR-B and c-Src kinase (wherein c-Src is activated by SH3-domain ligation with 
PR).31, 32, 36 In breast cancer models, rapid progesterone-induced MAPK 
activation (i.e. downstream of c-Src) or CDK2 robustly phosphorylates PR-B (but 
not PR-A) at Ser294.37, 38 In this context, PR-B Ser294 phosphorylation is 
required for regulation of selected target genes in either the absence (ex. IRS-2, 
STC1) or presence (ex. MSX2, RGS2, MAP1A, PDK4) of hormone.78 Thus, as 
expected, we observed robust ligand-induced phosphorylation of PR-B Ser294 in 
intact ES-2 cells (Figure 1D). However, in stark contrast to breast cancer models 
(i.e. where PR-A is not phosphorylated on Ser29479, 166), we were surprised to 
detect phosphorylation of PR-A Ser294 in intact ES-2 cells (Figure 1D). In breast 
cancer models, PR-B Ser294 phosphorylation confers hypersensitivity to 
progestin, increases the rate of ubiquitinylation of PR-B (an activation step for 
several SRs191), delays SUMOylation on K38879, promotes ligand-independent 
transcriptional activity110, and profoundly alters promoter selectivity.78 Ligand- or 
growth-factor-induced PR-A Ser294 phosphorylation is generally undetectable.79, 
166 Consistent with these findings, we demonstrated that PR-A K388 
SUMOylation (a transcriptionally repressive modification) occurs very rapidly (15 
mins) and is sustained relative to PR-B in response to progestin or progestin plus 
growth factor (EGF) treatment.79 Surprisingly, herein, we observed increased PR-
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A Ser294 phosphorylation when FOXO1-AAA was expressed in ES-2 ovarian 
cancer models, suggesting that activated FOXO1 may serve to co-recruit protein 
kinases capable of phosphorylating Ser294 to PR-A-containing complexes. 
Taken together, our data suggest that increased PR-A Ser294 phosphorylation in 
the presence of activated FOXO1 may account for its ability to transactivate PR-
B-specific target genes when these isoforms are co-expressed in PR-B+ cells 
(Figure 11). PR-A and PR-B cross-talk in the context of multiple post-translational 
modifications is a topic of further study. 
FOXO1 as a critical cofactor in ovarian cancer biology. 
 Herein, our data reveal a mechanism whereby PR isoforms may maintain 
either distinct or overlapping transcriptional gene programs via context-
dependent upregulation of key PR cofactors. PR-B but not PR-A induces 
FOXO1, the same pathway cofactor it requires to induce robust p21-dependent 
(i.e. via PR-B/FOXO1 complexes) cellular senescence in ovarian cancer cells.48 
In contrast, the relative in-availability of FOXO1 severely limits hormone-
sensitivity in ovarian cancer cells expressing PR-A. In PR-A+ ES-2 cells, ligand-
independent repression of FOXO1 mRNA may account for concomitant minimal 
regulation of p21 and p15 mRNAs and weak induction of cellular senescence 
when FOXO1 levels are also relatively low. Surprisingly, exogenous expression 
of active FOXO1 (FOXO1-AAA) restored hormone sensitivity in PR-A+ cells and 
conferred PR-B-like transcriptional activity at selected PR-B target genes (p21, 
GZMA, IGFBP1). In this context (PR-A plus activated FOXO1-AAA), progestin 
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induced a robust cellular senescence phenotype similar to that observed in PR-
B+ cells. Ultimately, our study underscores the critical importance of FOXO1 as a 
required cofactor for PR-dependent actions in the ovary.  
 Steroid hormone action in ovarian cancer is grossly understudied relative 
to breast or prostate cancers. There is an urgent need to focus on the early 
events related to the contribution of hormones in the context of altered signaling 
events (loss of p53 or PTEN, activation of AKT signaling) that may predispose 
women to increased risk of ovarian cancer. Deregulation of FOXO1 is associated 
with tumorigenesis and cancer progression across multiple cancer types. A 
recent PAthway Representation and Analysis by Direct Inference on Graphical 
Models (PARADIGM) analysis of mRNA expression and copy number data 
revealed 80 significant pathways altered in primary ovarian serous 
cystadenocarcinomas; the FoxO family signaling pathway was identified as 
significantly altered in this subtype.192 FOXO1 expression and activity is 
downregulated through alterations in upstream regulators, post-translational 
deregulation, or by genetic mutations121. Notably, AKT negatively regulates 
FOXO1 through phosphorylation and prevents FOXO1 nuclear accumulation, 
thus impairing target gene regulation.121 Activating mutations of PI3Ks or 
inactivating mutations (i.e. functional loss) of PTEN are common early events in 
ovarian cancer. For example, activated AKT (i.e. downstream of these events) 
may impair PR-induced senescence signaling by nuclear exclusion of FOXO1 
(Figure 8E). The early loss or inactivation of FOXO1 may render PR 
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“incompetent” at genes required for the induction of cellular senescence, leading 
to the loss of protective “sensing” by progesterone in ovarian tumors, and 
perhaps also in early PR+ breast tumors. Notably, analysis of The Cancer 
Genome Atlas data revealed significantly decreased FOXO1 mRNA expression 
in breast tumors relative to normal breast tissue (p<2.2x10-16). Thus, we propose 
that FOXO1 acts as a “molecular switch” that confers highly hormone-sensitive 
cell growth inhibition/senescence to PR+ epithelial cells, but may allow 
progesterone to stimulate proliferation in a highly context-dependent manner. 
Upon loss of FOXO1, PR interaction with other available co-factors may mediate 
profound changes in gene expression and associated cell biology (i.e. from 
senescence induction to activation of proliferative/pro-survival programs). For 
example, STAT3 and STAT5 appear to be primary cofactors that direct PR-B-
selective gene expression and increased breast cancer cell proliferation and 
survival.193-195 Furthermore, in proliferating (S-phase) breast cancer models, CK2 
confers ligand-independent PR-B target gene selection via phosphorylation of 
Ser81 (not found on PR-A) and recruitment of MKP3/DUSP6.195 These examples 
illustrate how early genetic events (i.e. mutations that alter kinase signaling) have 
profound consequences on SR-mediated (i.e. epigenetic) regulation of gene 
programs and associated changes in cell and cancer biology. 
 Our data highlight the requirement of FOXO1 for PR transcriptional 
regulation and specificity. A previous study demonstrated that constitutively 
active FOXO1 enhanced the ligand-dependent transcriptional activity of PR-A in 
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PRE-luciferase assays.147 One caveat of luciferase assays is that they primarily 
measure SR transcriptional activity when bound to minimal promoter elements in 
artificial contexts, limiting interpretations relevant to promoter selectivity during 
transcriptional regulation of endogenous gene promoters (i.e. in chromatin). 
Thus, while PR-A may appear to be “functional” in PRE-luciferase assays, it may 
repress selected endogenous genes in the context of chromatin. Herein, we 
validated that FOXO1 enhanced the ligand-dependent transcriptional activity of 
PR-A as measured via the levels of endogenous p21, GZMA, and IGFBP1 
mRNAs (ES-2 cells; and in HeLa cells for p21) and by readout of PRE-luciferase 
(HeLa cells). Furthermore, when we stably expressed the constitutively active 
FOXO1-AAA in PR-A+ ES-2 lacking detectable FOXO1, the sensitivity of PR-A to 
hormone was greatly enhanced and this formerly repressive isoform 
transactivated the p21 promoter (Figure 9). We conclude that constitutively active 
FOXO1 modulates PR-A hormone-sensitivity and influences the specificity of 
gene regulation, thereby mimicking the actions of PR-B. 
 In light of our findings herein, PR-B-dominance in ovarian tumors is 
intriguing. Early loss or inactivation of FOXO1 (i.e. via functional loss of PTEN 
and/or activation of PI3K/AKT signaling) is predicted to block induction of the 
senescence pathway, effectively “lifting” progesterone-mediated protection in PR-
B+ ovarian cancer cells.  It is tempting to speculate that in the absence of active 
FOXO1, PR-B acts as a driver of a proliferative/pro-survival transcriptional 
program similar to that observed in breast cancer models78, 171, 189, 195 In support 
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of this concept, flow cytometry experiments revealed a large spike in the 
percentage of PR-B+ ES-2 cells in S phase upon FOXO1 knock-down relative to 
shRNA controls.48 The context-dependent actions of PR-B in ovarian cancer 
models with chronically elevated AKT (i.e. inactivated FOXO1) signaling are a 
topic of further investigation. 
 While total PR levels are routinely measured in breast and endometrial 
cancers for clinical management and disease treatment, very few studies have 
examined the levels of PR isoforms in ovarian cancers. We collected a total of 
seven primary ovarian tumors and detected a dominance of PR-B-only in four 
tumors, while three tumors co-expressed PR-B and PR-A. In the ex vivo culture 
system, three high-grade serous ovarian tumors recapitulated our in vitro findings 
of PR-B-dependent induction of FOXO1 and/or p21 upon progestin treatment. As 
discussed above, aside from considerable tumor heterogeneity, several factors 
may account for lack of sensitivity to progestin in the other ovarian tumors; 
unresponsive tumors may harbor mutations that render FOXO1 inactive and 
unable to direct PR-dependent regulation of FOXO1 and p21 (i.e. required for 
senescence induction).  
In summary, our data reveal distinct tissue-specific actions of PR-A and 
PR-B in ovarian relative to extensively studied breast cancer models. Our 
observations have important clinical implications with regard to the development 
of isoform-specific and/or tissue-selective progestins for endocrine therapies. The 
ability of PR-A to inhibit hyperplastic proliferation in the uterus, together with 
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reduced proliferative activity when PR-A is activated in ovarian and mammary 
gland tissue strongly indicates that targeted activation of PR-A with isoform-
specific agonists will likely have a protective effect against uterine, breast, and 
ovarian carcinogenesis. Conversely, it may be desirable to inhibit the actions of 
PR-B, particularly when FOXO1 is inactivated in the context of heightened kinase 
signaling that is a hallmark of hormone-driven cancers. The quantification of PR 
isoforms and their key cofactors and target genes (i.e. FOXO1, p21) rather than 
total PR levels will be essential to improving the efficacy of disease management 
by isoform-specific selective PR modulators (SPRMs). 
 
3.5 ACKNOWLEDGEMENTS 
 We would like to thank members of the University of Minnesota Masonic 
Cancer Center’s Flow Cytometry Core Facility, the University Imaging Centers, 
the Minnesota Supercomputing Institute, and the University of Minnesota 
Genomics Center for their assistance in data acquisition, processing, and 
analysis. CDB-4124 (Proellex) was a kind gift from Ronald Wiehle (Repros 
Therapeutics). This study was supported by National Institutes of Health (NIH) 
grant R01 CA159712 and R01 CA159712-S1 (to C.A.L.), Cancer Biology 
Training Grant NIH T32 CA009138 (to C.H.D), National Center for Advancing 
Translational Sciences of the National Institutes of Health Award UL1TR000114 
(to C.H.D), and a University of Minnesota Doctoral Dissertation Fellowship 
(C.H.D.). 
  100 
 
3.6 CONFLICTS OF INTEREST 
The authors declare that they have no conflict of interest. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  101 
 
 
CHAPTER 4 
 
CONCLUSIONS 
 
4.1 SUMMARY 
 Mortality rates for ovarian cancer have remained largely unaffected 
despite clinical advances in detection methods, surgical techniques, and 
treatment regimens. Traditionally, ovarian cancer therapy has utilized extensive 
surgery followed by cytotoxic treatment strategies on the assumption that 
apoptotic tumor death increases the likelihood of increased patient survival. This 
strategy has limited treatment options to toxic compounds and high dose 
radiation for ovarian cancer patients. While these treatment strategies often yield 
partial to complete responses where the tumor shrinks or remains in remission, it 
can also cause severe side effects and toxicities in patients. Despite the initial 
treatment response, tumors often develop resistance and may reoccur or 
progress to advanced primary and metastatic tumors. An alternative strategy is 
the induction of cytostasis, where the proliferative capacity of tumor cells is 
permanently disabled without inducing apoptosis. Several clinical trials evaluating 
cytostatic treatments have yielded promising results,196-198 suggesting that these 
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treatments may be as effective as traditional cytotoxic therapies in preventing 
tumor growth with fewer and less severe side effects.  
 Therapy-induced senescence is a promising approach to the induction of 
cytostasis in proliferative tumors. Senescent cells remain viable and 
metabolically active, but are permanently growth arrested. Of clinical interest, 
some tumor cells can be forced into senescence in response to stress and 
damage caused by chemotherapeutic drugs and/or radiation.199 This suggests 
that many cancer cells posses intact, but repressed, signaling pathways that can 
be manipulated to undergo senescence. For example, low doses of doxorubicin 
induce senescence in numerous cancer cell lines, including those lacking tumor 
suppressors, p53 and p21.200 This suggests that signaling pathways for 
senescence remain competent in cancers and can be activated in a context-
dependent manner.  
 Herein, we have defined novel mechanisms for PR isoform-specific 
regulation of ovarian cancer cellular senescence in response to progesterone. 
We demonstrated that PR-A and PR-B-expressing ovarian cancer cells regulate 
distinct gene sets that differ from PR-driven gene sets in breast cancer cells. In 
ovarian cancer models, PR-A primarily regulates genes independently of 
progestin, while PR-B is the dominant ligand-dependent isoform. Ligand-
activated PR-B acts through a FOXO1-dependent mechanism to upregulate p15 
and p21 to robustly induce cellular senescence; PR-A represses FOXO1 and p21 
resulting in weak induction of cellular senescence relative to PR-B. The 
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overexpression of constitutively active FOXO1 (FOXO1-AAA) in PR-A-only 
expressing cells conferred robust ligand-dependent upregulation of PR-B-target 
genes (e.g. p21) and induced robust cellular senescence similar observed in PR-
B+ cells. Surprisingly, similar results were observed when PR-A was titrated into 
PR-B-containing cells, suggesting that FOXO1 confers transactivation of PR-B by 
PR-A. Finally, PR isoform-specific regulation of the FOXO1/p21 axis was 
recapitulated in seven human primary ovarian tumor explants treated with 
progestin. In summary, these data indicate a critical requirement for FOXO1 in 
progesterone signaling towards cellular senescence in ovarian cancer cells and 
reveals a novel mechanism for FOXO1 control of PR hormone sensitivity.   
 The dogma held that progesterone primarily acts through PR-B and is 
largely proliferative in the breast. However, in the reproductive track, 
progesterone was suspected to act primarily through PR-A isoforms as potent 
inhibitors of cell growth as PR-A is known to trans-repress the transcriptional 
activities of ER and PR-B. Our studies are the first to demonstrate that PR-B is a 
tumor suppressor and a mediator of ovarian cancer cellular senescence48, yet 
the same receptor is clearly proliferative in the normal and cancerous breast.170, 
180 In addition, our studies are the first to demonstrate that PR-A trans-activates 
PR-B transcriptional activity in ovarian cancer cells, yet the same receptor trans-
represses PR-B activity in breast cancer cells. The molecular mechanism of our 
findings involves the requirement for the interaction between FOXO1 and PR-A 
and PR-B in the ovary at tumor suppressor genes (i.e. p21, p15). The same 
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tumor suppressor genes are regulated in cancerous breast tissue, but to a 
weaker intensity; this weakened response may be due to post-translational 
modifications (i.e. phosphorylation) of PR that are specific to developing breast 
cancer.  
 In addition, the dogma held that PR-A and PR-B are differentially 
susceptible to post-translational modifications in response to the same kinase 
and hormone stimulation. This complexity contributes to the distinctions between 
the genes they activate. For example, PR-B, but not PR-A, is robustly 
phosphorylated on Ser294 in response to progestin and MAPK activation in 
breast cancer cells. In contrast, detection of PR-A Ser294 phosphorylation is low 
to unmeasurable in intact breast cancer cells, but exhibits increased K388 
SUMOylation (a transcriptionally repressive modification).79 Our studies are the 
first to demonstrate that PR-A can be robustly phosphorylated on Ser294 in 
response to progestin when FOXO1 is present and active. Increased PR-A 
Ser294 phosphorylation was detected when FOXO1-AAA was expressed in ES-2 
ovarian cancer models relative to expression of the empty vector control, 
suggesting that activated FOXO1 may serve to co-recruit protein kinases capable 
of phosphorylating Ser294 to PR-A-containing complexes. Taken together, our 
data suggest that increased PR-A Ser294 phosphorylation in the presence of 
activated FOXO1 may account for its ability to transactivate PR-B-specific target 
genes when these isoforms are co-expressed in PR-B+ cells.  
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 Collectively, our studies suggest FOXO1 is a critical determinant of PR 
isoform transcriptional activity as it acts as a rheostat and pioneer factor for 
progesterone and PR to inhibit cell growth in ovarian cancer. In PR-A-expressing 
cells, FOXO1 is repressed in a ligand-independent manner relative to PR-B-
expressing cells; progestin treatment in PR-A+ cells minimally regulates FOXO1 
mRNA levels at late timepoints (96 hr) but modestly induces senescence. When 
a certain threshold of FOXO1 expression achieved, either by basal expression in 
progestin-treated PR-B+ cells or by overexpression of constitutively active 
FOXO1 (FOXO1-AAA), PR-A sensitivity to progestin is restored and its 
transcriptional activity mimics PR-B on selectively PR-B target genes, such as 
p21, GZMA, and IGFBP1. FOXO1, like other members of the Forkhead domain 
family, may act as a pioneer factor in PR-expressing cells. As pioneer factors, 
FOX proteins can associate with compacted chromatin and modulate chromatin 
to facilitate accessibility for other transcription factors201, such as PR. Previously, 
we presented evidence for the requirement of FOXO1 for the binding of PR-B to 
DNA on a commonly regulated PR-B/FOXO1 gene, p21. Stable knock-down of 
FOXO1 reduced PR-B recruitment to the p21 promoter and ablated progestin-
dependent upregulation of p21, thereby decreasing induction of senescence. A 
recent study evaluating the co-occupancy of FOXO1 and PR cistromes in 
decidualized primary human endometrial stromal cells confirmed the intimate 
crosstalk between FOXO1 and PR, as 75% of FOXO1 binding sites overlapped 
with PR binding sites.202 PR binding enrichment on shared PR and FOXO1 
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genomic sites was decreased when FOXO1 was silenced, suggesting that 
chromatin accessibility for PR was lost and FOXO1 is required for PR binding to 
target genes.      
 Similar to breast studies, we suspect that PR isoforms in ovarian cancer 
models are also exquisitely sensitive to kinase inputs that may alter this 
biological outcome. Both PR and FOXO1 are tightly regulated by phosphorylation 
events. Hormone-driven breast and gynecologic cancers frequently exhibit 
upregulated protein kinases, such as MAPK164, CDK2203, and CK276, which 
directly phosphorylate and modulate PR-B target gene selectivity. Notably, the 
same kinases that are recruited to PR-B in “rapid” signaling (i.e. extra-nuclear) 
complexes (i.e. CDK2 and MAPK) also inhibit FOXO1 via regulation of specific 
phosphorylation sites that favor nuclear export.204 Deregulation of FOXO1 is 
associated with tumorigenesis and cancer progression. FOXO1 is downregulated 
in several carcinomas, including ovarian101, through alterations in upstream 
regulators, post-translational deregulation, or by genetic mutations.121 
Specifically, AKT-mediated serine/threonine phospho-regulation of FOXO1 is 
well-defined and prevents FOXO1 nuclear accumulation, thus impairing target 
gene regulation.121 As mutations of PI3Ks or PTEN are common early events in 
cancer (particularly in breast, uterine, and ovarian cancers), activated AKT and 
other mitogenic protein kinases may prevent PR-induced senescence signaling 
by nuclear exclusion of FOXO1. Thus, the early loss or inactivation of FOXO1 
may render PR “incompetent” at genes required for the induction of cellular 
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senescence, leading to the loss of protective “sensing” by progesterone in 
ovarian tumors. Whether these events may redirect PR to “alternate” genes that 
instead favor tumor progression are unknown and a topic for further study. 
 
4.2 FUTURE DIRECTIONS 
 Other treatment regimens, such as hormonal therapy have been 
evaluated for ovarian cancer. The use of progestins alone (megestrol acetate 
and medroxyprogesterone acetate) as ovarian cancer therapies have been 
examined in several relatively small phase II clinical trials with variable inclusion 
criteria and modest response rates.129 However, retrospective studies evaluating 
the association of total PR expression and progression-free disease survival8, 11-
18, 49 support the concept that subsets of PR-positive ovarian tumors are highly 
sensitive to hormones and thus more likely to respond to endocrine therapy. It is 
likely that the ovarian tumors that exhibited modest response rates to progestin 
therapy in the clinical trials were PR-positive and became senescent over the 
course of treatment evaluation. Since growth arrested senescent cells cannot 
further divide, but depend upon specific kinase-mediated signal transduction 
pathways for prolonged survival, this population of cells may be more vulnerable 
to subsequent therapies that inhibit mitogenic protein kinases and thereby 
promote apoptosis. We hypothesize that senescent cancer cells become 
“oncogene addicted” to protein kinase-initiated signaling pathways, and the 
combination of kinase inhibitors with progestin treatment may cause a dramatic 
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increase in cell death in PR+ cells. The induction of senescence followed by 
targeting key effectors of pro-survival to apoptosis in senescent cancer cells may 
improve the efficacy of both treatment strategies as a cancer therapy. 
  While elegant models have recently emerged 205, 206, knowledge gaps still 
exist. What are the best methods and experimental models to elucidate 
progesterone-specific effects in hormone-responsive tumors? While breast and 
ovarian cancers are diagnosed in both pre- and post-menopausal populations, a 
majority of the current cell-based models were originally established from post-
menopausal patients. To understand steroid receptor actions, cells are treated 
with varying concentrations of exogenous hormones that may or may not reflect 
true physiological levels experienced in a pre-menopausal (cyclical hormone 
exposure) or post-menopausal (constant/low hormone exposure) context. Are the 
hormone concentrations used in the laboratory relevant to these contexts and 
thus to the biology of the tumors that arise? In addition, decreased PR 
expression is associated with progression of disease in breast and gynecologic 
cancers,207, 208 whereas over 50% of acquired endocrine-resistant breast tumors 
retain PR expression.209, 210 How do breast and other tumors lose PR expression 
and/or regain it during extended periods of endocrine (anti-estrogen therapy)? 
How should we model these changes? Concerning in vitro models, PR 
expression is often lost when primary isolates or immortalized cell lines are 
continuously cultured on 2D surfaces. The development of co-culture or 3D 
models may more accurately reflect in vivo cellular architecture relevant to 
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paracrine signaling and tumor biology211 and will allow a more accurate 
characterization of the mechanisms and biological effects of hormone and 
antitumor treatments. Finally, routine detection and quantification of individual PR 
isoforms in clinical samples may provide valuable information as potentially 
distinct biomarkers of tumor behavior that could be used to further guide 
endocrine therapy. 
 Understanding how PRs function differentially in each normal and 
neoplastic tissue type will reveal how these highly modified receptors can be 
therapeutically targeted, perhaps as separate isoforms, to favor one biological 
outcome (growth inhibition, senescence, apoptosis) over another (proliferation, 
survival). Ultimately, in order to effectively manipulate PR action 
pharmacologically to treat tumors arising from different tissue types we must first 
appreciate their mechanistic complexity. Isoform-specific ligands as activators or 
inhibitors would be a valuable set of tools to accomplish this goal. In the current 
age of cancer genomics and personalized medicine, clinical readouts of PR-
driven gene signatures may provide an additional means to discern context-
dependent protective versus deleterious PR actions present in individual tissues 
and tumors.  
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